^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

Study Identifier      Unique Subject Identifier
Subject Identifier for the Study
Study Site                     Date/Time               Age
Identifier            Country  of Birth           Age  Units
                                                      Pooled
                                                         Age
                                                       Group
Pooled Age Group 1                                     1 (N)
                                                      Pooled
                                                         Age
                                                       Group
Pooled Age Group 2                                     2 (N)
Sex   Sex (N)
                                                    Subject
                                                    Identifier
                                                    for Study
Race                                                for Listing
Age/Sex          Age/Race/Sex
                                                    Ethnicity
Ethnicity                                                 (N)
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                    Baseline
                        Body  Date/Time               Date/Time
Baseline  Baseline      Mass  of             Date of  of First
  Weight    Height     Index  Informed      Informed  Study
    (kg)      (cm)  (kg/m^2)  Consent        Consent  Treatment
Date/Time   Subject     Subject
of Last     Reference   Reference
Study       Start       Stop        Description of
Treatment   Date/Time   Date/Time   Actual Arm
Description of        Description of     Description of
Actual Arm Code       Planned Arm        Planned Arm Code
                Planned                   Actual    Date of
Planned       Treatment  Actual        Treatment      First
Treatment           for  Treatment           for   Exposure
for Period       Period  for Period       Period         to
01               01 (N)  01               01 (N)  Treatment
  Date of
     Last
 Exposure  Safety      Enrolled    PK          PD
       to  Population  Population  Population  Population
Treatment  Flag        Flag        Flag        Flag
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                                  Modified  Completed  PTSD
RAND        Screened    Full      Full      Safety     Diagnosis
Population  Population  Analysis  Analysis  Follow-up  History
Flag        Flag        set Flag  Set       Flg        Flag
                                           Discon.
   Date of                                 Early from
 Birth (N)  Investigator Name              Study
  Discon.
    Early
     from
    Study
     Date  Reas. for Disc. Early from Study
Reas. for
Disc. Early
from Study,
Spcy.         Discon.  Early from study Trt.
              Reas. for
Reas. for     Early                                Subject
Disc. of      Discon. from  Date/Time     Date of  Death
Study Trt.    study Trt.    of Death        Death  Flag
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

           Completed
Completed  Efficacy                 Childbearing
Efficacy   Follow-up  Childbearing     Potential
Follow-up  at Week    Potential      for Females
at Week 4  12         for Females            (N)
                                        Subj on      Subj on
                           Concomitant  stable        stable
                                Use of  dose of      dose of
Concomitant Use              SSRI/SNRI  SSRI/SNRI  SSRI/SNRI
of SSRI/SNRI                       (N)  IRT          IRT (N)
Subj on      Subj on
stable        stable
dose of      dose of
SSRI/SNRI  SSRI/SNRI
EDC          EDC (N)      SITE    site_n      trtn  trt
          Analysis                  Planned
          Sequence  Planned       Treatment  Actual
 SITEIDN    Number  Treatment           (N)  Treatment
   Actual  Analysis
Treatment     Visit  Analysis         Visit
      (N)       (N)  Visit           Number  Visit
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

Analysis
  Window
   Visit  Analysis      Parameter
     (N)  Window Visit  Code
                                          Baseline
                                          Record    Analaysis
Parameter                                 Flag           Date
          Analysis  Analysis
Analysis     Date/  Relative  Parameter     Parameter
    Time      Time       Day  Category 1    Category 2
                                            Percentage
                                    Change      Change
Analysis  Analysis      Baseline      from        from
   Value  Value (C)        Value  Baseline    Baseline
 Duration
       of  Time-Dependent  Time-Dependent  Time-Dependent
Treatment       covariate       covariate       covariate
 in Weeks      for Week 1      for Week 4      for Week 8
                              Criterion
                              1
Time-Dependent                Evaluation
 covariate for  Analysis      Result      Analysis
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

       Week 12  Criterion 1   Flag        Criterion 2
Criterion                 Criterion                 Criterion
2                         3                         4
Evaluation                Evaluation                Evaluation
Result      Analysis      Result      Analysis      Result
Flag        Criterion 3   Flag        Criterion 4   Flag
Analysis  Analysis  Analysis
Record    Record    Record
Flag 01   Flag 02   Flag 03
ƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒ
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

JZP150-201            JZP150-201-1063-1001                    
10631001                                          
1063                  USA      1987-03-10          35  YEARS
<=65 years                                                 1
<=45 years                                                 1
F           2
WHITE                                               10631001/35/
                                                    F/W         
35/F             35/W/F      
Hispanic or Latino                                          1
    88.5     170.2      31.2  2022-08-17  2022-08-17  2022-09-14
2022-11-06  2022-09-14  2022-11-06  Dummy Treatment C
C                     Dummy Treatment C  C                   
Placebo               3  Placebo               3  14SEP2022
06NOV2022  Y           Y                                 
Y           Y           Y         Y         N          N        
1987-03-10  Charles (Brendan) Montano      ONGOING     
                                                             
              ONGOING                                           
                                                          
N          N          N                        2
Absence                              2  No                 2
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

No                 2      1063         1         3  Placebo     
       1       357  Placebo               3  Placebo     
        3         0  Baseline             0  Baseline    
       0  Baseline      PTSDTSEV 
PTSD total - Severity                     Y             22901
                          -1  CAPS-5 Past   PTSD totals 
                              Week          - Sum of    
                                            subtotals   
                                            (B+C+D+E)   
      51  51                  51                      
        8               0               0               0
             1                                        
                                                              
Y                   Y       
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

JZP150-201            JZP150-201-1063-1002                    
10631002                                          
1063                  USA      1997-07-22          25  YEARS
<=65 years                                                 1
<=45 years                                                 1
F           2
WHITE                                               10631002/25/
                                                    F/W         
25/F             25/W/F      
Non-Hispanic or Latino                                      2
    71.2     157.5      28.0  2022-09-12  2022-09-12  2022-10-04
2022-11-06  2022-10-04  2022-11-06  Dummy Treatment A
A                     Dummy Treatment A  A                   
JZP150 0.3            1  JZP150 0.3            1  04OCT2022
mg                       mg                                
06NOV2022  Y           Y                                 
Y           Y           Y         Y         N          N        
1997-07-22  Charles (Brendan) Montano      ONGOING     
                                                             
              ONGOING                                           
                                                          
N          N          Y                        1
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

Presence                             1  Yes                1
Yes                1      1063         1         1  JZP150 0.3  
                                                    mg          
       1       357  JZP150 0.3            1  JZP150 0.3  
                    mg                       mg          
        1         0  Baseline             0  Baseline    
       0  Baseline      PTSDTSEV 
PTSD total - Severity                     Y             22921
                          -1  CAPS-5 Past   PTSD totals 
                              Week          - Sum of    
                                            subtotals   
                                            (B+C+D+E)   
      52  52                  52                      
        5               0               0               1
             2                                        
                                                              
Y                   Y       
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

JZP150-201            JZP150-201-1063-1003                    
10631003                                          
1063                  USA      2001-06-28          21  YEARS
<=65 years                                                 1
<=45 years                                                 1
F           2
BLACK OR AFRICAN AMERICAN                           10631003/21/
                                                    F/B         
21/F             21/B/F      
Hispanic or Latino                                          1
    57.2     154.9      21.5  2022-09-19  2022-09-19  2022-10-14
2022-11-06  2022-10-14  2022-11-06  Dummy Treatment C
C                     Dummy Treatment C  C                   
Placebo               3  Placebo               3  14OCT2022
06NOV2022  Y           Y                                 
Y           Y           Y         Y         N          N        
2001-06-28  Charles (Brendan) Montano      ONGOING     
                                                             
              ONGOING                                           
                                                          
N          N          Y                        1
Presence                             1  Yes                1
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

Yes                1      1063         1         3  Placebo     
       1       179  Placebo               3  Placebo     
        3         0  Baseline             0  Baseline    
       0  Baseline      PTSDTSEV 
PTSD total - Severity                     Y             22930
                          -2  CAPS-5 Past   PTSD totals 
                              Week          - Sum of    
                                            subtotals   
                                            (B+C+D+E)   
      42  42                  42                      
        3               0               1               2
             2                                        
                                                              
Y                   Y       
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

Study Identifier      Unique Subject Identifier
Subject Identifier for the Study
Study Site                     Date/Time               Age
Identifier            Country  of Birth           Age  Units
                                                      Pooled
                                                         Age
                                                       Group
Pooled Age Group 1                                     1 (N)
                                                      Pooled
                                                         Age
                                                       Group
Pooled Age Group 2                                     2 (N)
Sex   Sex (N)
                                                    Subject
                                                    Identifier
                                                    for Study
Race                                                for Listing
Age/Sex          Age/Race/Sex
                                                    Ethnicity
Ethnicity                                                 (N)
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                    Baseline
                        Body  Date/Time               Date/Time
Baseline  Baseline      Mass  of             Date of  of First
  Weight    Height     Index  Informed      Informed  Study
    (kg)      (cm)  (kg/m^2)  Consent        Consent  Treatment
Date/Time   Subject     Subject
of Last     Reference   Reference
Study       Start       Stop        Description of
Treatment   Date/Time   Date/Time   Actual Arm
Description of        Description of     Description of
Actual Arm Code       Planned Arm        Planned Arm Code
                Planned                   Actual    Date of
Planned       Treatment  Actual        Treatment      First
Treatment           for  Treatment           for   Exposure
for Period       Period  for Period       Period         to
01               01 (N)  01               01 (N)  Treatment
  Date of
     Last
 Exposure  Safety      Enrolled    PK          PD
       to  Population  Population  Population  Population
Treatment  Flag        Flag        Flag        Flag
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                                  Modified  Completed  PTSD
RAND        Screened    Full      Full      Safety     Diagnosis
Population  Population  Analysis  Analysis  Follow-up  History
Flag        Flag        set Flag  Set       Flg        Flag
                                           Discon.
   Date of                                 Early from
 Birth (N)  Investigator Name              Study
  Discon.
    Early
     from
    Study
     Date  Reas. for Disc. Early from Study
Reas. for
Disc. Early
from Study,
Spcy.         Discon.  Early from study Trt.
              Reas. for
Reas. for     Early                                Subject
Disc. of      Discon. from  Date/Time     Date of  Death
Study Trt.    study Trt.    of Death        Death  Flag
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

           Completed
Completed  Efficacy                 Childbearing
Efficacy   Follow-up  Childbearing     Potential
Follow-up  at Week    Potential      for Females
at Week 4  12         for Females            (N)
                                        Subj on      Subj on
                           Concomitant  stable        stable
                                Use of  dose of      dose of
Concomitant Use              SSRI/SNRI  SSRI/SNRI  SSRI/SNRI
of SSRI/SNRI                       (N)  IRT          IRT (N)
Subj on      Subj on
stable        stable
dose of      dose of
SSRI/SNRI  SSRI/SNRI
EDC          EDC (N)      SITE    site_n      trtn  trt
          Analysis                  Planned
          Sequence  Planned       Treatment  Actual
 SITEIDN    Number  Treatment           (N)  Treatment
   Actual  Analysis
Treatment     Visit  Analysis         Visit
      (N)       (N)  Visit           Number  Visit
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

Analysis
  Window
   Visit  Analysis      Parameter
     (N)  Window Visit  Code
                                          Baseline
                                          Record    Analaysis
Parameter                                 Flag           Date
          Analysis  Analysis
Analysis     Date/  Relative  Parameter     Parameter
    Time      Time       Day  Category 1    Category 2
                                            Percentage
                                    Change      Change
Analysis  Analysis      Baseline      from        from
   Value  Value (C)        Value  Baseline    Baseline
 Duration
       of  Time-Dependent  Time-Dependent  Time-Dependent
Treatment       covariate       covariate       covariate
 in Weeks      for Week 1      for Week 4      for Week 8
                              Criterion
                              1
Time-Dependent                Evaluation
 covariate for  Analysis      Result      Analysis
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

       Week 12  Criterion 1   Flag        Criterion 2
Criterion                 Criterion                 Criterion
2                         3                         4
Evaluation                Evaluation                Evaluation
Result      Analysis      Result      Analysis      Result
Flag        Criterion 3   Flag        Criterion 4   Flag
Analysis  Analysis  Analysis
Record    Record    Record
Flag 01   Flag 02   Flag 03
ƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒ
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

JZP150-201            JZP150-201-1160-1002                    
11601002                                          
1160                  USA      1982-07-16          40  YEARS
<=65 years                                                 1
<=45 years                                                 1
F           2
WHITE                                               11601002/40/
                                                    F/W         
40/F             40/W/F      
Non-Hispanic or Latino                                      2
    89.5     164.0      33.2  2022-07-25  2022-07-25  2022-08-02
2022-08-18  2022-08-02  2022-08-18  Dummy Treatment C
C                     Dummy Treatment C  C                   
Placebo               3  Placebo               3  02AUG2022
18AUG2022  Y           Y                                 
Y           Y           Y         Y         N          N        
1982-07-16  Muhammad Saleem Ismail         DISCONTINUED
18AUG2022  ADVERSE EVENT                                     
AE001-        DISCONTINUED                                      
INCREASING                                                      
DEPRESSION                                                      
SYMPTOMS-18                                                     
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

AUG                                                             
2022;SUBJECT                                                    
REPORTED                                                        
INCREASED                                                       
DEPRESSION                                                      
AND TIME                                                        
CONSTRAINTS                                                     
WITH NEW JOB                                                    
WITHDRAWAL    TIME                                        
OF CONSENT    CONSTRAINTS                                 
BY STUDY      AT WORK AND                                 
PARTICIPANT   SUBJECT                                     
              EXPERIENCED                                 
              HIGH AND                                    
              LOWS SINCE                                  
              STARTING IP                                 
N          N          Y                        1
Absence                              2  No                 2
No                 2      1160         2         3  Placebo     
       2       179  Placebo               3  Placebo     
        3         0  Baseline             0  Baseline    
       0  Baseline      PTSDTSEV 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

PTSD total - Severity                     Y             22858
                          -1  CAPS-5 Past   PTSD totals 
                              Week          - Sum of    
                                            subtotals   
                                            (B+C+D+E)   
      25  25                  25                      
        2               0               1               2
             2                                        
                                                              
Y                   Y       
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

JZP150-201            JZP150-201-1160-1006                    
11601006                                          
1160                  USA      1965-03-03          57  YEARS
<=65 years                                                 1
>45 years                                                  2
M           1
BLACK OR AFRICAN AMERICAN                           11601006/57/
                                                    M/B         
57/M             57/B/M      
Non-Hispanic or Latino                                      2
   116.9     184.5      34.6  2022-09-13  2022-09-13  2022-09-27
2022-10-04  2022-09-27  2022-10-04  Dummy Treatment C
C                     Dummy Treatment C  C                   
Placebo               3  Placebo               3  27SEP2022
04OCT2022  Y           Y                                 
Y           Y           Y         Y         N          N        
1965-03-03  Muhammad Saleem Ismail         ONGOING     
                                                             
              ONGOING                                           
                                                          
N          N                                    
Absence                              2  No                 2
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

No                 2      1160         2         3  Placebo     
       2       357  Placebo               3  Placebo     
        3         0  Baseline             0  Baseline    
       0  Baseline      PTSDTSEV 
PTSD total - Severity                     Y             22914
                          -1  CAPS-5 Past   PTSD totals 
                              Week          - Sum of    
                                            subtotals   
                                            (B+C+D+E)   
      36  36                  36                      
        1               0               1               2
             2                                        
                                                              
Y                   Y       
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

JZP150-201            JZP150-201-1160-1007                    
11601007                                          
1160                  USA      1958-06-15          64  YEARS
<=65 years                                                 1
>45 years                                                  2
F           2
WHITE                                               11601007/64/
                                                    F/W         
64/F             64/W/F      
Non-Hispanic or Latino                                      2
    71.5     157.5      28.5  2022-10-10  2022-10-10  2022-10-21
2022-11-06  2022-10-21  2022-11-06  Dummy Treatment A
A                     Dummy Treatment A  A                   
JZP150 0.3            1  JZP150 0.3            1  21OCT2022
mg                       mg                                
06NOV2022  Y           Y                                 
Y           Y           Y         Y         N          N        
1958-06-15  Muhammad Saleem Ismail         ONGOING     
                                                             
              ONGOING                                           
                                                          
N          N          N                        2
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

Presence                             1  Yes                1
Yes                1      1160         2         1  JZP150 0.3  
                                                    mg          
       2       179  JZP150 0.3            1  JZP150 0.3  
                    mg                       mg          
        1         0  Baseline             0  Baseline    
       0  Baseline      PTSDTSEV 
PTSD total - Severity                     Y             22938
                          -1  CAPS-5 Past   PTSD totals 
                              Week          - Sum of    
                                            subtotals   
                                            (B+C+D+E)   
      37  37                  37                      
        2               0               1               2
             2                                        
                                                              
Y                   Y       
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

Study Identifier      Unique Subject Identifier
Subject Identifier for the Study
Study Site                     Date/Time               Age
Identifier            Country  of Birth           Age  Units
                                                      Pooled
                                                         Age
                                                       Group
Pooled Age Group 1                                     1 (N)
                                                      Pooled
                                                         Age
                                                       Group
Pooled Age Group 2                                     2 (N)
Sex   Sex (N)
                                                    Subject
                                                    Identifier
                                                    for Study
Race                                                for Listing
Age/Sex          Age/Race/Sex
                                                    Ethnicity
Ethnicity                                                 (N)
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                    Baseline
                        Body  Date/Time               Date/Time
Baseline  Baseline      Mass  of             Date of  of First
  Weight    Height     Index  Informed      Informed  Study
    (kg)      (cm)  (kg/m^2)  Consent        Consent  Treatment
Date/Time   Subject     Subject
of Last     Reference   Reference
Study       Start       Stop        Description of
Treatment   Date/Time   Date/Time   Actual Arm
Description of        Description of     Description of
Actual Arm Code       Planned Arm        Planned Arm Code
                Planned                   Actual    Date of
Planned       Treatment  Actual        Treatment      First
Treatment           for  Treatment           for   Exposure
for Period       Period  for Period       Period         to
01               01 (N)  01               01 (N)  Treatment
  Date of
     Last
 Exposure  Safety      Enrolled    PK          PD
       to  Population  Population  Population  Population
Treatment  Flag        Flag        Flag        Flag
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                                  Modified  Completed  PTSD
RAND        Screened    Full      Full      Safety     Diagnosis
Population  Population  Analysis  Analysis  Follow-up  History
Flag        Flag        set Flag  Set       Flg        Flag
                                           Discon.
   Date of                                 Early from
 Birth (N)  Investigator Name              Study
  Discon.
    Early
     from
    Study
     Date  Reas. for Disc. Early from Study
Reas. for
Disc. Early
from Study,
Spcy.         Discon.  Early from study Trt.
              Reas. for
Reas. for     Early                                Subject
Disc. of      Discon. from  Date/Time     Date of  Death
Study Trt.    study Trt.    of Death        Death  Flag
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

           Completed
Completed  Efficacy                 Childbearing
Efficacy   Follow-up  Childbearing     Potential
Follow-up  at Week    Potential      for Females
at Week 4  12         for Females            (N)
                                        Subj on      Subj on
                           Concomitant  stable        stable
                                Use of  dose of      dose of
Concomitant Use              SSRI/SNRI  SSRI/SNRI  SSRI/SNRI
of SSRI/SNRI                       (N)  IRT          IRT (N)
Subj on      Subj on
stable        stable
dose of      dose of
SSRI/SNRI  SSRI/SNRI
EDC          EDC (N)      SITE    site_n      trtn  trt
          Analysis                  Planned
          Sequence  Planned       Treatment  Actual
 SITEIDN    Number  Treatment           (N)  Treatment
   Actual  Analysis
Treatment     Visit  Analysis         Visit
      (N)       (N)  Visit           Number  Visit
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

Analysis
  Window
   Visit  Analysis      Parameter
     (N)  Window Visit  Code
                                          Baseline
                                          Record    Analaysis
Parameter                                 Flag           Date
          Analysis  Analysis
Analysis     Date/  Relative  Parameter     Parameter
    Time      Time       Day  Category 1    Category 2
                                            Percentage
                                    Change      Change
Analysis  Analysis      Baseline      from        from
   Value  Value (C)        Value  Baseline    Baseline
 Duration
       of  Time-Dependent  Time-Dependent  Time-Dependent
Treatment       covariate       covariate       covariate
 in Weeks      for Week 1      for Week 4      for Week 8
                              Criterion
                              1
Time-Dependent                Evaluation
 covariate for  Analysis      Result      Analysis
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

       Week 12  Criterion 1   Flag        Criterion 2
Criterion                 Criterion                 Criterion
2                         3                         4
Evaluation                Evaluation                Evaluation
Result      Analysis      Result      Analysis      Result
Flag        Criterion 3   Flag        Criterion 4   Flag
Analysis  Analysis  Analysis
Record    Record    Record
Flag 01   Flag 02   Flag 03
ƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒ
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

JZP150-201            JZP150-201-1303-1001                    
13031001                                          
1303                  USA      1982-02-15          40  YEARS
<=65 years                                                 1
<=45 years                                                 1
F           2
BLACK OR AFRICAN AMERICAN                           13031001/40/
                                                    F/B         
40/F             40/B/F      
Non-Hispanic or Latino                                      2
    80.6     167.6      28.2  2022-04-28  2022-04-28  2022-05-14
2022-08-05  2022-05-14  2022-09-16  Dummy Treatment C
C                     Dummy Treatment C  C                   
Placebo               3  Placebo               3  14MAY2022
05AUG2022  Y           Y                                 
Y           Y           Y         Y         Y          N        
1982-02-15  Olga Lapeyra                   COMPLETED   
16SEP2022                                                    
              COMPLETED                                         
                                                          
N          N          Y                        1
Absence                              2  No                 2
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

No                 2      1303         3         3  Placebo     
       3       535  Placebo               3  Placebo     
        3         0  Baseline             0  Baseline    
       0  Baseline      PTSDTSEV 
PTSD total - Severity                     Y             22778
                          -1  CAPS-5 Past   PTSD totals 
                              Week          - Sum of    
                                            subtotals   
                                            (B+C+D+E)   
      35  35                  35                      
       12               0               0               0
             0                                        
                                                              
Y                   Y       
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

JZP150-201            JZP150-201-1303-1001                    
13031001                                          
1303                  USA      1982-02-15          40  YEARS
<=65 years                                                 1
<=45 years                                                 1
F           2
BLACK OR AFRICAN AMERICAN                           13031001/40/
                                                    F/B         
40/F             40/B/F      
Non-Hispanic or Latino                                      2
    80.6     167.6      28.2  2022-04-28  2022-04-28  2022-05-14
2022-08-05  2022-05-14  2022-09-16  Dummy Treatment C
C                     Dummy Treatment C  C                   
Placebo               3  Placebo               3  14MAY2022
05AUG2022  Y           Y                                 
Y           Y           Y         Y         Y          N        
1982-02-15  Olga Lapeyra                   COMPLETED   
16SEP2022                                                    
              COMPLETED                                         
                                                          
N          N          Y                        1
Absence                              2  No                 2
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

No                 2      1303         3         3  Placebo     
       3       537  Placebo               3  Placebo     
        3        12  Week 12             12  Week 12     
      12  Week 12       PTSDTSEV 
PTSD total - Severity                                   22862
                          84  CAPS-5 Past   PTSD totals 
                              Week          - Sum of    
                                            subtotals   
                                            (B+C+D+E)   
      13  13                  35       -22    -62.8571
       12               0               0               0
             0                            < 30%       
                                          improvement 
                                          on the      
                                          CAPS-5 total
                                          score from  
                                          Baseline to 
                                          Week 12     
Y                                                             
Y                   Y       
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

JZP150-201            JZP150-201-1303-1002                    
13031002                                          
1303                  USA      1994-07-08          28  YEARS
<=65 years                                                 1
<=45 years                                                 1
F           2
WHITE                                               13031002/28/
                                                    F/W         
28/F             28/W/F      
Non-Hispanic or Latino                                      2
    69.4     160.0      27.1  2022-08-19  2022-08-19  2022-09-13
2022-11-06  2022-09-13  2022-11-06  Dummy Treatment C
C                     Dummy Treatment C  C                   
Placebo               3  Placebo               3  13SEP2022
06NOV2022  Y           Y                                 
Y           Y           Y         Y         N          N        
1994-07-08  Olga Lapeyra                   ONGOING     
                                                             
              ONGOING                                           
                                                          
N          N          Y                        1
Absence                              2  No                 2
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

No                 2      1303         3         3  Placebo     
       3       357  Placebo               3  Placebo     
        3         0  Baseline             0  Baseline    
       0  Baseline      PTSDTSEV 
PTSD total - Severity                                   22901
                           1  CAPS-5 Past   PTSD totals 
                              Week          - Sum of    
                                            subtotals   
                                            (B+C+D+E)   
      25  25                                          
        8               0               0               0
             1                                        
                                                              
Y                   Y       
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

JZP150-201            JZP150-201-1303-1004                    
13031004                                          
1303                  USA      1961-01-04          61  YEARS
<=65 years                                                 1
>45 years                                                  2
M           1
WHITE                                               13031004/61/
                                                    M/W         
61/M             61/W/M      
Non-Hispanic or Latino                                      2
    76.6     178.0      24.9  2022-09-21  2022-09-21  2022-10-14
2022-11-06  2022-10-14  2022-11-06  Dummy Treatment B
B                     Dummy Treatment B  B                   
JZP150 4 mg           2  JZP150 4 mg           2  14OCT2022
06NOV2022  Y           Y                                 
Y           Y           Y         Y         N          N        
1961-01-04  Olga Lapeyra                   ONGOING     
                                                             
              ONGOING                                           
                                                          
N          N                                    
Absence                              2  No                 2
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

No                 2      1303         3         2  JZP150 4 mg 
       3       179  JZP150 4 mg           2  JZP150 4 mg 
        2         0  Baseline             0  Baseline    
       0  Baseline      PTSDTSEV 
PTSD total - Severity                     Y             22930
                          -2  CAPS-5 Past   PTSD totals 
                              Week          - Sum of    
                                            subtotals   
                                            (B+C+D+E)   
      48  48                  48                      
        3               0               1               2
             2                                        
                                                              
Y                   Y       
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

Study Identifier      Unique Subject Identifier
Subject Identifier for the Study
Study Site                     Date/Time               Age
Identifier            Country  of Birth           Age  Units
                                                      Pooled
                                                         Age
                                                       Group
Pooled Age Group 1                                     1 (N)
                                                      Pooled
                                                         Age
                                                       Group
Pooled Age Group 2                                     2 (N)
Sex   Sex (N)
                                                    Subject
                                                    Identifier
                                                    for Study
Race                                                for Listing
Age/Sex          Age/Race/Sex
                                                    Ethnicity
Ethnicity                                                 (N)
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                    Baseline
                        Body  Date/Time               Date/Time
Baseline  Baseline      Mass  of             Date of  of First
  Weight    Height     Index  Informed      Informed  Study
    (kg)      (cm)  (kg/m^2)  Consent        Consent  Treatment
Date/Time   Subject     Subject
of Last     Reference   Reference
Study       Start       Stop        Description of
Treatment   Date/Time   Date/Time   Actual Arm
Description of        Description of     Description of
Actual Arm Code       Planned Arm        Planned Arm Code
                Planned                   Actual    Date of
Planned       Treatment  Actual        Treatment      First
Treatment           for  Treatment           for   Exposure
for Period       Period  for Period       Period         to
01               01 (N)  01               01 (N)  Treatment
  Date of
     Last
 Exposure  Safety      Enrolled    PK          PD
       to  Population  Population  Population  Population
Treatment  Flag        Flag        Flag        Flag
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                                  Modified  Completed  PTSD
RAND        Screened    Full      Full      Safety     Diagnosis
Population  Population  Analysis  Analysis  Follow-up  History
Flag        Flag        set Flag  Set       Flg        Flag
                                           Discon.
   Date of                                 Early from
 Birth (N)  Investigator Name              Study
  Discon.
    Early
     from
    Study
     Date  Reas. for Disc. Early from Study
Reas. for
Disc. Early
from Study,
Spcy.         Discon.  Early from study Trt.
              Reas. for
Reas. for     Early                                Subject
Disc. of      Discon. from  Date/Time     Date of  Death
Study Trt.    study Trt.    of Death        Death  Flag
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

           Completed
Completed  Efficacy                 Childbearing
Efficacy   Follow-up  Childbearing     Potential
Follow-up  at Week    Potential      for Females
at Week 4  12         for Females            (N)
                                        Subj on      Subj on
                           Concomitant  stable        stable
                                Use of  dose of      dose of
Concomitant Use              SSRI/SNRI  SSRI/SNRI  SSRI/SNRI
of SSRI/SNRI                       (N)  IRT          IRT (N)
Subj on      Subj on
stable        stable
dose of      dose of
SSRI/SNRI  SSRI/SNRI
EDC          EDC (N)      SITE    site_n      trtn  trt
          Analysis                  Planned
          Sequence  Planned       Treatment  Actual
 SITEIDN    Number  Treatment           (N)  Treatment
   Actual  Analysis
Treatment     Visit  Analysis         Visit
      (N)       (N)  Visit           Number  Visit
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

Analysis
  Window
   Visit  Analysis      Parameter
     (N)  Window Visit  Code
                                          Baseline
                                          Record    Analaysis
Parameter                                 Flag           Date
          Analysis  Analysis
Analysis     Date/  Relative  Parameter     Parameter
    Time      Time       Day  Category 1    Category 2
                                            Percentage
                                    Change      Change
Analysis  Analysis      Baseline      from        from
   Value  Value (C)        Value  Baseline    Baseline
 Duration
       of  Time-Dependent  Time-Dependent  Time-Dependent
Treatment       covariate       covariate       covariate
 in Weeks      for Week 1      for Week 4      for Week 8
                              Criterion
                              1
Time-Dependent                Evaluation
 covariate for  Analysis      Result      Analysis
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

       Week 12  Criterion 1   Flag        Criterion 2
Criterion                 Criterion                 Criterion
2                         3                         4
Evaluation                Evaluation                Evaluation
Result      Analysis      Result      Analysis      Result
Flag        Criterion 3   Flag        Criterion 4   Flag
Analysis  Analysis  Analysis
Record    Record    Record
Flag 01   Flag 02   Flag 03
ƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒ
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

JZP150-201            JZP150-201-1358-1001                    
13581001                                          
1358                  USA      1974-12-10          47  YEARS
<=65 years                                                 1
>45 years                                                  2
F           2
WHITE                                               13581001/47/
                                                    F/W         
47/F             47/W/F      
Non-Hispanic or Latino                                      2
    64.0     163.8      24.0  2021-12-29  2021-12-29  2022-01-20
2022-01-28  2022-01-20  2022-02-01  Dummy Treatment C
C                     Dummy Treatment C  C                   
Placebo               3  Placebo               3  20JAN2022
28JAN2022  Y           Y                                 
Y           Y           Y         Y         N          N        
1974-12-10  Elias Sarkis                   DISCONTINUED
01FEB2022  WITHDRAWAL BY PARTICIPANT                         
W/D OF        DISCONTINUED                                      
CONSENT BY                                                      
STUDY                                                           
PARTICIPANT                                                     
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

WITHDRAWAL    W/D OF                                      
OF CONSENT    CONSENT BY                                  
BY STUDY      STUDY                                       
PARTICIPANT   PARTICIPANT                                 
N          N          Y                        1
Absence                              2  No                 2
No                 2      1358         4         3  Placebo     
       4       357  Placebo               3  Placebo     
        3         0  Baseline             0  Baseline    
       0  Baseline      PTSDTSEV 
PTSD total - Severity                     Y             22664
                          -1  CAPS-5 Past   PTSD totals 
                              Week          - Sum of    
                                            subtotals   
                                            (B+C+D+E)   
      33  33                  33                      
        1               0               1               2
             2                                        
                                                              
Y                   Y       
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

JZP150-201            JZP150-201-1358-1010                    
13581010                                          
1358                  USA      1967-08-20          54  YEARS
<=65 years                                                 1
>45 years                                                  2
F           2
WHITE                                               13581010/54/
                                                    F/W         
54/F             54/W/F      
Non-Hispanic or Latino                                      2
    70.8     170.2      26.0  2022-05-06  2022-05-06  2022-05-21
2022-06-02  2022-05-21  2022-06-20  Dummy Treatment C
C                     Dummy Treatment C  C                   
Placebo               3  Placebo               3  21MAY2022
02JUN2022  Y           Y                                 
Y           Y           Y         Y         N          N        
1967-08-20  Elias Sarkis                   DISCONTINUED
20JUN2022  WITHDRAWAL BY PARTICIPANT                         
UNABLE TO     DISCONTINUED                                      
CONTINUE                                                        
CLINIC VISIT                                                    
SCHEDULE PER                                                    
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

SUBJECT                                                         
WITHDRAWAL    SUBJECT ET                                  
OF CONSENT    AND WITHDREW                                
BY STUDY      CONSENT ON                                  
PARTICIPANT   20 JUN 2022                                 
              DUE TO                                      
              "UNABLE TO                                  
              MEET STUDY                                  
              VISIT                                       
              REQUIREMENTS                                
              ."                                          
N          N          N                        2
Absence                              2  No                 2
No                 2      1358         4         3  Placebo     
       4       179  Placebo               3  Placebo     
        3         0  Baseline             0  Baseline    
       0  Baseline      PTSDTSEV 
PTSD total - Severity                     Y             22785
                          -1  CAPS-5 Past   PTSD totals 
                              Week          - Sum of    
                                            subtotals   
                                            (B+C+D+E)   
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

      54  54                  54                      
        2               0               1               2
             2                                        
                                                              
Y                   Y       
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

JZP150-201            JZP150-201-1358-1014                    
13581014                                          
1358                  USA      2000-05-23          22  YEARS
<=65 years                                                 1
<=45 years                                                 1
F           2
WHITE                                               13581014/22/
                                                    F/W         
22/F             22/W/F      
Hispanic or Latino                                          1
    50.8     153.7      21.3  2022-06-07  2022-06-07  2022-07-06
2022-07-11  2022-07-06  2022-07-14  Dummy Treatment C
C                     Dummy Treatment C  C                   
Placebo               3  Placebo               3  06JUL2022
11JUL2022  Y           Y                                 
Y           Y           Y         Y         N          N        
2000-05-23  Elias Sarkis                   DISCONTINUED
14JUL2022  ADVERSE EVENT                                     
AE001-"       DISCONTINUED                                      
EXTREMELY                                                       
DROWSY"-06                                                      
JUL 2022                                                        
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

ADVERSE       AE001-"                                     
EVENT         EXTREMELY                                   
              DROWSY"-06                                  
              JUL 2022                                    
N          N          Y                        1
Absence                              2  No                 2
No                 2      1358         4         3  Placebo     
       4       357  Placebo               3  Placebo     
        3         0  Baseline             0  Baseline    
       0  Baseline      PTSDTSEV 
PTSD total - Severity                     Y             22831
                          -1  CAPS-5 Past   PTSD totals 
                              Week          - Sum of    
                                            subtotals   
                                            (B+C+D+E)   
      60  60                  60                      
        1               0               1               2
             2                                        
                                                              
Y                   Y       
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

Study Identifier      Unique Subject Identifier
Subject Identifier for the Study
Study Site                     Date/Time               Age
Identifier            Country  of Birth           Age  Units
                                                      Pooled
                                                         Age
                                                       Group
Pooled Age Group 1                                     1 (N)
                                                      Pooled
                                                         Age
                                                       Group
Pooled Age Group 2                                     2 (N)
Sex   Sex (N)
                                                    Subject
                                                    Identifier
                                                    for Study
Race                                                for Listing
Age/Sex          Age/Race/Sex
                                                    Ethnicity
Ethnicity                                                 (N)
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                    Baseline
                        Body  Date/Time               Date/Time
Baseline  Baseline      Mass  of             Date of  of First
  Weight    Height     Index  Informed      Informed  Study
    (kg)      (cm)  (kg/m^2)  Consent        Consent  Treatment
Date/Time   Subject     Subject
of Last     Reference   Reference
Study       Start       Stop        Description of
Treatment   Date/Time   Date/Time   Actual Arm
Description of        Description of     Description of
Actual Arm Code       Planned Arm        Planned Arm Code
                Planned                   Actual    Date of
Planned       Treatment  Actual        Treatment      First
Treatment           for  Treatment           for   Exposure
for Period       Period  for Period       Period         to
01               01 (N)  01               01 (N)  Treatment
  Date of
     Last
 Exposure  Safety      Enrolled    PK          PD
       to  Population  Population  Population  Population
Treatment  Flag        Flag        Flag        Flag
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                                  Modified  Completed  PTSD
RAND        Screened    Full      Full      Safety     Diagnosis
Population  Population  Analysis  Analysis  Follow-up  History
Flag        Flag        set Flag  Set       Flg        Flag
                                           Discon.
   Date of                                 Early from
 Birth (N)  Investigator Name              Study
  Discon.
    Early
     from
    Study
     Date  Reas. for Disc. Early from Study
Reas. for
Disc. Early
from Study,
Spcy.         Discon.  Early from study Trt.
              Reas. for
Reas. for     Early                                Subject
Disc. of      Discon. from  Date/Time     Date of  Death
Study Trt.    study Trt.    of Death        Death  Flag
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

           Completed
Completed  Efficacy                 Childbearing
Efficacy   Follow-up  Childbearing     Potential
Follow-up  at Week    Potential      for Females
at Week 4  12         for Females            (N)
                                        Subj on      Subj on
                           Concomitant  stable        stable
                                Use of  dose of      dose of
Concomitant Use              SSRI/SNRI  SSRI/SNRI  SSRI/SNRI
of SSRI/SNRI                       (N)  IRT          IRT (N)
Subj on      Subj on
stable        stable
dose of      dose of
SSRI/SNRI  SSRI/SNRI
EDC          EDC (N)      SITE    site_n      trtn  trt
          Analysis                  Planned
          Sequence  Planned       Treatment  Actual
 SITEIDN    Number  Treatment           (N)  Treatment
   Actual  Analysis
Treatment     Visit  Analysis         Visit
      (N)       (N)  Visit           Number  Visit
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

Analysis
  Window
   Visit  Analysis      Parameter
     (N)  Window Visit  Code
                                          Baseline
                                          Record    Analaysis
Parameter                                 Flag           Date
          Analysis  Analysis
Analysis     Date/  Relative  Parameter     Parameter
    Time      Time       Day  Category 1    Category 2
                                            Percentage
                                    Change      Change
Analysis  Analysis      Baseline      from        from
   Value  Value (C)        Value  Baseline    Baseline
 Duration
       of  Time-Dependent  Time-Dependent  Time-Dependent
Treatment       covariate       covariate       covariate
 in Weeks      for Week 1      for Week 4      for Week 8
                              Criterion
                              1
Time-Dependent                Evaluation
 covariate for  Analysis      Result      Analysis
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

       Week 12  Criterion 1   Flag        Criterion 2
Criterion                 Criterion                 Criterion
2                         3                         4
Evaluation                Evaluation                Evaluation
Result      Analysis      Result      Analysis      Result
Flag        Criterion 3   Flag        Criterion 4   Flag
Analysis  Analysis  Analysis
Record    Record    Record
Flag 01   Flag 02   Flag 03
ƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒ
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

JZP150-201            JZP150-201-1381-1002                    
13811002                                          
1381                  USA      1985-03-17          37  YEARS
<=65 years                                                 1
<=45 years                                                 1
M           1
WHITE                                               13811002/37/
                                                    M/W         
37/M             37/W/M      
Non-Hispanic or Latino                                      2
    79.0     182.0      23.9  2022-04-28  2022-04-28  2022-05-23
2022-11-06  2022-05-23  2022-07-13  Dummy Treatment A
A                     Dummy Treatment A  A                   
JZP150 0.3            1  JZP150 0.3            1  23MAY2022
mg                       mg                                
06NOV2022  Y           Y                                 
Y           Y           Y         Y         N          N        
1985-03-17  Emilio Mantero Atineza         DISCONTINUED
13JUL2022  LOST TO FU                                        
LOST TO FU    DISCONTINUED                                      
LOST TO       LOST TO                                     
FOLLOW-UP     FOLLOW-UP                                   
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

N          N                                    
Absence                              2  No                 2
No                 2      1381         5         1  JZP150 0.3  
                                                    mg          
       5       179  JZP150 0.3            1  JZP150 0.3  
                    mg                       mg          
        1         0  Baseline             0  Baseline    
       0  Baseline      PTSDTSEV 
PTSD total - Severity                                   22788
                           1  CAPS-5 Past   PTSD totals 
                              Week          - Sum of    
                                            subtotals   
                                            (B+C+D+E)   
      37  37                                          
       24               0               0               0
             0                                        
                                                              
Y                   Y       
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

Study Identifier      Unique Subject Identifier
Subject Identifier for the Study
Study Site                     Date/Time               Age
Identifier            Country  of Birth           Age  Units
                                                      Pooled
                                                         Age
                                                       Group
Pooled Age Group 1                                     1 (N)
                                                      Pooled
                                                         Age
                                                       Group
Pooled Age Group 2                                     2 (N)
Sex   Sex (N)
                                                    Subject
                                                    Identifier
                                                    for Study
Race                                                for Listing
Age/Sex          Age/Race/Sex
                                                    Ethnicity
Ethnicity                                                 (N)
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                    Baseline
                        Body  Date/Time               Date/Time
Baseline  Baseline      Mass  of             Date of  of First
  Weight    Height     Index  Informed      Informed  Study
    (kg)      (cm)  (kg/m^2)  Consent        Consent  Treatment
Date/Time   Subject     Subject
of Last     Reference   Reference
Study       Start       Stop        Description of
Treatment   Date/Time   Date/Time   Actual Arm
Description of        Description of     Description of
Actual Arm Code       Planned Arm        Planned Arm Code
                Planned                   Actual    Date of
Planned       Treatment  Actual        Treatment      First
Treatment           for  Treatment           for   Exposure
for Period       Period  for Period       Period         to
01               01 (N)  01               01 (N)  Treatment
  Date of
     Last
 Exposure  Safety      Enrolled    PK          PD
       to  Population  Population  Population  Population
Treatment  Flag        Flag        Flag        Flag
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                                  Modified  Completed  PTSD
RAND        Screened    Full      Full      Safety     Diagnosis
Population  Population  Analysis  Analysis  Follow-up  History
Flag        Flag        set Flag  Set       Flg        Flag
                                           Discon.
   Date of                                 Early from
 Birth (N)  Investigator Name              Study
  Discon.
    Early
     from
    Study
     Date  Reas. for Disc. Early from Study
Reas. for
Disc. Early
from Study,
Spcy.         Discon.  Early from study Trt.
              Reas. for
Reas. for     Early                                Subject
Disc. of      Discon. from  Date/Time     Date of  Death
Study Trt.    study Trt.    of Death        Death  Flag
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

           Completed
Completed  Efficacy                 Childbearing
Efficacy   Follow-up  Childbearing     Potential
Follow-up  at Week    Potential      for Females
at Week 4  12         for Females            (N)
                                        Subj on      Subj on
                           Concomitant  stable        stable
                                Use of  dose of      dose of
Concomitant Use              SSRI/SNRI  SSRI/SNRI  SSRI/SNRI
of SSRI/SNRI                       (N)  IRT          IRT (N)
Subj on      Subj on
stable        stable
dose of      dose of
SSRI/SNRI  SSRI/SNRI
EDC          EDC (N)      SITE    site_n      trtn  trt
          Analysis                  Planned
          Sequence  Planned       Treatment  Actual
 SITEIDN    Number  Treatment           (N)  Treatment
   Actual  Analysis
Treatment     Visit  Analysis         Visit
      (N)       (N)  Visit           Number  Visit
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

Analysis
  Window
   Visit  Analysis      Parameter
     (N)  Window Visit  Code
                                          Baseline
                                          Record    Analaysis
Parameter                                 Flag           Date
          Analysis  Analysis
Analysis     Date/  Relative  Parameter     Parameter
    Time      Time       Day  Category 1    Category 2
                                            Percentage
                                    Change      Change
Analysis  Analysis      Baseline      from        from
   Value  Value (C)        Value  Baseline    Baseline
 Duration
       of  Time-Dependent  Time-Dependent  Time-Dependent
Treatment       covariate       covariate       covariate
 in Weeks      for Week 1      for Week 4      for Week 8
                              Criterion
                              1
Time-Dependent                Evaluation
 covariate for  Analysis      Result      Analysis
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

       Week 12  Criterion 1   Flag        Criterion 2
Criterion                 Criterion                 Criterion
2                         3                         4
Evaluation                Evaluation                Evaluation
Result      Analysis      Result      Analysis      Result
Flag        Criterion 3   Flag        Criterion 4   Flag
Analysis  Analysis  Analysis
Record    Record    Record
Flag 01   Flag 02   Flag 03
ƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒ
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

JZP150-201            JZP150-201-1399-1001                    
13991001                                          
1399                  USA      1960-09-28          61  YEARS
<=65 years                                                 1
>45 years                                                  2
F           2
WHITE                                               13991001/61/
                                                    F/W         
61/F             61/W/F      
Hispanic or Latino                                          1
    86.4     157.5      34.8  2022-06-17  2022-06-17  2022-07-09
2022-07-12  2022-07-09  2022-09-22  Dummy Treatment B
B                     Dummy Treatment B  B                   
JZP150 4 mg           2  JZP150 4 mg           2  09JUL2022
12JUL2022  Y           Y                                 
Y           Y           Y         Y         N          N        
1960-09-28  Lissette Selem                 DISCONTINUED
22SEP2022  ENROLLED IN ERROR                                 
ENROLLED IN   DISCONTINUED                                      
ERROR                                                           
ENROLLED IN   LOW FAILURE                                 
ERROR         SCORE ON                                    
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

              PCL-5.                                      
N          Y          N                        2
Absence                              2  No                 2
No                 2      1399         6         2  JZP150 4 mg 
       6       535  JZP150 4 mg           2  JZP150 4 mg 
        2         0  Baseline             0  Baseline    
       0  Baseline      PTSDTSEV 
PTSD total - Severity                     Y             22834
                          -1  CAPS-5 Past   PTSD totals 
                              Week          - Sum of    
                                            subtotals   
                                            (B+C+D+E)   
       0  0                    0                      
        1               0               1               2
             2                                        
                                                              
Y                   Y       
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

JZP150-201            JZP150-201-1399-1002                    
13991002                                          
1399                  USA      1998-12-22          23  YEARS
<=65 years                                                 1
<=45 years                                                 1
F           2
WHITE                                               13991002/23/
                                                    F/W         
23/F             23/W/F      
Hispanic or Latino                                          1
    77.2     158.5      31.0  2022-07-13  2022-07-13  2022-07-29
2022-10-18  2022-07-29  2022-11-01  Dummy Treatment A
A                     Dummy Treatment A  A                   
JZP150 0.3            1  JZP150 0.3            1  29JUL2022
mg                       mg                                
18OCT2022  Y           Y                                 
Y           Y           Y         Y         Y          N        
1998-12-22  Lissette Selem                 COMPLETED   
01NOV2022                                                    
              COMPLETED                                         
                                                          
N          N          Y                        1
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

Absence                              2  No                 2
No                 2      1399         6         1  JZP150 0.3  
                                                    mg          
       6       535  JZP150 0.3            1  JZP150 0.3  
                    mg                       mg          
        1         0  Baseline             0  Baseline    
       0  Baseline      PTSDTSEV 
PTSD total - Severity                     Y             22854
                          -1  CAPS-5 Past   PTSD totals 
                              Week          - Sum of    
                                            subtotals   
                                            (B+C+D+E)   
      36  36                  36                      
       12               0               0               0
             0                                        
                                                              
Y                   Y       
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

JZP150-201            JZP150-201-1399-1002                    
13991002                                          
1399                  USA      1998-12-22          23  YEARS
<=65 years                                                 1
<=45 years                                                 1
F           2
WHITE                                               13991002/23/
                                                    F/W         
23/F             23/W/F      
Hispanic or Latino                                          1
    77.2     158.5      31.0  2022-07-13  2022-07-13  2022-07-29
2022-10-18  2022-07-29  2022-11-01  Dummy Treatment A
A                     Dummy Treatment A  A                   
JZP150 0.3            1  JZP150 0.3            1  29JUL2022
mg                       mg                                
18OCT2022  Y           Y                                 
Y           Y           Y         Y         Y          N        
1998-12-22  Lissette Selem                 COMPLETED   
01NOV2022                                                    
              COMPLETED                                         
                                                          
N          N          Y                        1
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

Absence                              2  No                 2
No                 2      1399         6         1  JZP150 0.3  
                                                    mg          
       6       537  JZP150 0.3            1  JZP150 0.3  
                    mg                       mg          
        1        12  Week 12             12  Week 12     
      12  Week 12       PTSDTSEV 
PTSD total - Severity                                   22936
                          82  CAPS-5 Past   PTSD totals 
                              Week          - Sum of    
                                            subtotals   
                                            (B+C+D+E)   
      21  21                  36       -15    -41.6667
       12               0               0               0
             0                            < 30%       
                                          improvement 
                                          on the      
                                          CAPS-5 total
                                          score from  
                                          Baseline to 
                                          Week 12     
Y                                                             
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

Y                   Y       
JZP150-201            JZP150-201-1399-1004                    
13991004                                          
1399                  USA      1998-03-03          24  YEARS
<=65 years                                                 1
<=45 years                                                 1
M           1
WHITE                                               13991004/24/
                                                    M/W         
24/M             24/W/M      
Hispanic or Latino                                          1
    92.5     180.3      28.4  2022-08-11  2022-08-11  2022-09-13
2022-11-06  2022-09-13  2022-11-06  Dummy Treatment A
A                     Dummy Treatment A  A                   
JZP150 0.3            1  JZP150 0.3            1  13SEP2022
mg                       mg                                
06NOV2022  Y           Y                                 
Y           Y           Y         Y         N          N        
1998-03-03  Lissette Selem                 ONGOING     
                                                             
              ONGOING                                           
                                                          
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

N          N                                    
Absence                              2  No                 2
No                 2      1399         6         1  JZP150 0.3  
                                                    mg          
       6       357  JZP150 0.3            1  JZP150 0.3  
                    mg                       mg          
        1         0  Baseline             0  Baseline    
       0  Baseline      PTSDTSEV 
PTSD total - Severity                     Y             22900
                          -1  CAPS-5 Past   PTSD totals 
                              Week          - Sum of    
                                            subtotals   
                                            (B+C+D+E)   
      34  34                  34                      
        8               0               0               0
             1                                        
                                                              
Y                   Y       
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

JZP150-201            JZP150-201-1399-1007                    
13991007                                          
1399                  USA      1958-04-26          64  YEARS
<=65 years                                                 1
>45 years                                                  2
F           2
BLACK OR AFRICAN AMERICAN                           13991007/64/
                                                    F/B         
64/F             64/B/F      
Non-Hispanic or Latino                                      2
    71.2     161.3      27.2  2022-09-07  2022-09-07  2022-10-01
2022-11-06  2022-10-01  2022-11-06  Dummy Treatment A
A                     Dummy Treatment A  A                   
JZP150 0.3            1  JZP150 0.3            1  01OCT2022
mg                       mg                                
06NOV2022  Y           Y                                 
Y           Y           Y         Y         N          N        
1958-04-26  Lissette Selem                 ONGOING     
                                                             
              ONGOING                                           
                                                          
N          N          N                        2
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

Absence                              2  No                 2
No                 2      1399         6         1  JZP150 0.3  
                                                    mg          
       6       357  JZP150 0.3            1  JZP150 0.3  
                    mg                       mg          
        1         0  Baseline             0  Baseline    
       0  Baseline      PTSDTSEV 
PTSD total - Severity                     Y             22918
                          -1  CAPS-5 Past   PTSD totals 
                              Week          - Sum of    
                                            subtotals   
                                            (B+C+D+E)   
      33  33                  33                      
        5               0               0               1
             2                                        
                                                              
Y                   Y       
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

JZP150-201            JZP150-201-1399-1009                    
13991009                                          
1399                  USA      1957-11-22          64  YEARS
<=65 years                                                 1
>45 years                                                  2
M           1
BLACK OR AFRICAN AMERICAN                           13991009/64/
                                                    M/B         
64/M             64/B/M      
Non-Hispanic or Latino                                      2
    79.4     182.9      23.7  2022-09-20  2022-09-20  2022-10-19
2022-11-06  2022-10-19  2022-11-06  Dummy Treatment A
A                     Dummy Treatment A  A                   
JZP150 0.3            1  JZP150 0.3            1  19OCT2022
mg                       mg                                
06NOV2022  Y           Y                                 
Y           Y           Y         Y         N          N        
1957-11-22  Lissette Selem                 ONGOING     
                                                             
              ONGOING                                           
                                                          
N          N                                    
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

Absence                              2  No                 2
No                 2      1399         6         1  JZP150 0.3  
                                                    mg          
       6       179  JZP150 0.3            1  JZP150 0.3  
                    mg                       mg          
        1         0  Baseline             0  Baseline    
       0  Baseline      PTSDTSEV 
PTSD total - Severity                     Y             22936
                          -1  CAPS-5 Past   PTSD totals 
                              Week          - Sum of    
                                            subtotals   
                                            (B+C+D+E)   
      11  11                  11                      
        3               0               1               2
             2                                        
                                                              
Y                   Y       
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

JZP150-201            JZP150-201-1399-1010                    
13991010                                          
1399                  USA      1959-09-08          63  YEARS
<=65 years                                                 1
>45 years                                                  2
M           1
WHITE                                               13991010/63/
                                                    M/W         
63/M             63/W/M      
Non-Hispanic or Latino                                      2
    79.8     170.7      27.4  2022-09-22  2022-09-22  2022-10-15
2022-11-06  2022-10-15  2022-11-06  Dummy Treatment B
B                     Dummy Treatment B  B                   
JZP150 4 mg           2  JZP150 4 mg           2  15OCT2022
06NOV2022  Y           Y                                 
Y           Y           Y         Y         N          N        
1959-09-08  Lissette Selem                 ONGOING     
                                                             
              ONGOING                                           
                                                          
N          N                                    
Absence                              2  No                 2
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

No                 2      1399         6         2  JZP150 4 mg 
       6       179  JZP150 4 mg           2  JZP150 4 mg 
        2         0  Baseline             0  Baseline    
       0  Baseline      PTSDTSEV 
PTSD total - Severity                     Y             22932
                          -1  CAPS-5 Past   PTSD totals 
                              Week          - Sum of    
                                            subtotals   
                                            (B+C+D+E)   
      38  38                  38                      
        3               0               1               2
             2                                        
                                                              
Y                   Y       
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

Study Identifier      Unique Subject Identifier
Subject Identifier for the Study
Study Site                     Date/Time               Age
Identifier            Country  of Birth           Age  Units
                                                      Pooled
                                                         Age
                                                       Group
Pooled Age Group 1                                     1 (N)
                                                      Pooled
                                                         Age
                                                       Group
Pooled Age Group 2                                     2 (N)
Sex   Sex (N)
                                                    Subject
                                                    Identifier
                                                    for Study
Race                                                for Listing
Age/Sex          Age/Race/Sex
                                                    Ethnicity
Ethnicity                                                 (N)
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                    Baseline
                        Body  Date/Time               Date/Time
Baseline  Baseline      Mass  of             Date of  of First
  Weight    Height     Index  Informed      Informed  Study
    (kg)      (cm)  (kg/m^2)  Consent        Consent  Treatment
Date/Time   Subject     Subject
of Last     Reference   Reference
Study       Start       Stop        Description of
Treatment   Date/Time   Date/Time   Actual Arm
Description of        Description of     Description of
Actual Arm Code       Planned Arm        Planned Arm Code
                Planned                   Actual    Date of
Planned       Treatment  Actual        Treatment      First
Treatment           for  Treatment           for   Exposure
for Period       Period  for Period       Period         to
01               01 (N)  01               01 (N)  Treatment
  Date of
     Last
 Exposure  Safety      Enrolled    PK          PD
       to  Population  Population  Population  Population
Treatment  Flag        Flag        Flag        Flag
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                                  Modified  Completed  PTSD
RAND        Screened    Full      Full      Safety     Diagnosis
Population  Population  Analysis  Analysis  Follow-up  History
Flag        Flag        set Flag  Set       Flg        Flag
                                           Discon.
   Date of                                 Early from
 Birth (N)  Investigator Name              Study
  Discon.
    Early
     from
    Study
     Date  Reas. for Disc. Early from Study
Reas. for
Disc. Early
from Study,
Spcy.         Discon.  Early from study Trt.
              Reas. for
Reas. for     Early                                Subject
Disc. of      Discon. from  Date/Time     Date of  Death
Study Trt.    study Trt.    of Death        Death  Flag
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

           Completed
Completed  Efficacy                 Childbearing
Efficacy   Follow-up  Childbearing     Potential
Follow-up  at Week    Potential      for Females
at Week 4  12         for Females            (N)
                                        Subj on      Subj on
                           Concomitant  stable        stable
                                Use of  dose of      dose of
Concomitant Use              SSRI/SNRI  SSRI/SNRI  SSRI/SNRI
of SSRI/SNRI                       (N)  IRT          IRT (N)
Subj on      Subj on
stable        stable
dose of      dose of
SSRI/SNRI  SSRI/SNRI
EDC          EDC (N)      SITE    site_n      trtn  trt
          Analysis                  Planned
          Sequence  Planned       Treatment  Actual
 SITEIDN    Number  Treatment           (N)  Treatment
   Actual  Analysis
Treatment     Visit  Analysis         Visit
      (N)       (N)  Visit           Number  Visit
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

Analysis
  Window
   Visit  Analysis      Parameter
     (N)  Window Visit  Code
                                          Baseline
                                          Record    Analaysis
Parameter                                 Flag           Date
          Analysis  Analysis
Analysis     Date/  Relative  Parameter     Parameter
    Time      Time       Day  Category 1    Category 2
                                            Percentage
                                    Change      Change
Analysis  Analysis      Baseline      from        from
   Value  Value (C)        Value  Baseline    Baseline
 Duration
       of  Time-Dependent  Time-Dependent  Time-Dependent
Treatment       covariate       covariate       covariate
 in Weeks      for Week 1      for Week 4      for Week 8
                              Criterion
                              1
Time-Dependent                Evaluation
 covariate for  Analysis      Result      Analysis
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

       Week 12  Criterion 1   Flag        Criterion 2
Criterion                 Criterion                 Criterion
2                         3                         4
Evaluation                Evaluation                Evaluation
Result      Analysis      Result      Analysis      Result
Flag        Criterion 3   Flag        Criterion 4   Flag
Analysis  Analysis  Analysis
Record    Record    Record
Flag 01   Flag 02   Flag 03
ƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒ
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

JZP150-201            JZP150-201-1659-1001                    
16591001                                          
1659                  USA      1965-11-20          56  YEARS
<=65 years                                                 1
>45 years                                                  2
F           2
WHITE                                               16591001/56/
                                                    F/W         
56/F             56/W/F      
Non-Hispanic or Latino                                      2
    80.0     165.1      29.1  2022-01-20  2022-01-20  2022-02-09
2022-02-27  2022-02-09  2022-03-15  Dummy Treatment A
A                     Dummy Treatment A  A                   
JZP150 0.3            1  JZP150 0.3            1  09FEB2022
mg                       mg                                
27FEB2022  Y           Y                                 
Y           Y           Y         Y         N          Y        
1965-11-20  Walter Duffy                   DISCONTINUED
15MAR2022  ADVERSE EVENT                                     
AE001-        DISCONTINUED                                      
BRONCHITIS-                                                     
14 FEB 2022                                                     
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

ADVERSE       AE001-                                      
EVENT         BRONCHITIS-                                 
              14 FEB 2022                                 
N          N          N                        2
Absence                              2  No                 2
No                 2      1659         7         1  JZP150 0.3  
                                                    mg          
       7       357  JZP150 0.3            1  JZP150 0.3  
                    mg                       mg          
        1         0  Baseline             0  Baseline    
       0  Baseline      PTSDTSEV 
PTSD total - Severity                     Y             22684
                          -1  CAPS-5 Past   PTSD totals 
                              Week          - Sum of    
                                            subtotals   
                                            (B+C+D+E)   
      52  52                  52                      
        3               0               1               2
             2                                        
                                                              
Y                   Y       
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

JZP150-201            JZP150-201-1659-1003                    
16591003                                          
1659                  USA      1964-12-29          57  YEARS
<=65 years                                                 1
>45 years                                                  2
F           2
WHITE                                               16591003/57/
                                                    F/W         
57/F             57/W/F      
Non-Hispanic or Latino                                      2
    72.3     162.5      27.2  2022-01-26  2022-01-26  2022-02-16
2022-03-22  2022-02-16  2022-04-07  Dummy Treatment B
B                     Dummy Treatment B  B                   
JZP150 4 mg           2  JZP150 4 mg           2  16FEB2022
22MAR2022  Y           Y                                 
Y           Y           Y         Y         N          N        
1964-12-29  Walter Duffy                   DISCONTINUED
07APR2022  ADVERSE EVENT                                     
AE001-        DISCONTINUED                                      
INSOMNIA-17                                                     
FEB 2022                                                        
ADVERSE       AE001-                                      
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

EVENT         INSOMNIA-17                                 
              FEB 2022                                    
N          N          N                        2
Absence                              2  No                 2
No                 2      1659         7         2  JZP150 4 mg 
       7       535  JZP150 4 mg           2  JZP150 4 mg 
        2         0  Baseline             0  Baseline    
       0  Baseline      PTSDTSEV 
PTSD total - Severity                     Y             22691
                          -1  CAPS-5 Past   PTSD totals 
                              Week          - Sum of    
                                            subtotals   
                                            (B+C+D+E)   
      56  56                  56                      
        5               0               0               1
             2                                        
                                                              
Y                   Y       
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

JZP150-201            JZP150-201-1659-1006                    
16591006                                          
1659                  USA      1988-04-29          33  YEARS
<=65 years                                                 1
<=45 years                                                 1
F           2
WHITE                                               16591006/33/
                                                    F/W         
33/F             33/W/F      
Non-Hispanic or Latino                                      2
    63.9     165.1      24.3  2022-03-08  2022-03-08  2022-03-22
2022-06-13  2022-03-22  2022-06-29  Dummy Treatment B
B                     Dummy Treatment B  B                   
JZP150 4 mg           2  JZP150 4 mg           2  22MAR2022
13JUN2022  Y           Y                                 
Y           Y           Y         Y         Y          Y        
1988-04-29  Walter Duffy                   COMPLETED   
29JUN2022                                                    
              COMPLETED                                         
                                                          
N          N          N                        2
Absence                              2  No                 2
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

No                 2      1659         7         2  JZP150 4 mg 
       7       535  JZP150 4 mg           2  JZP150 4 mg 
        2         0  Baseline             0  Baseline    
       0  Baseline      PTSDTSEV 
PTSD total - Severity                     Y             22725
                          -1  CAPS-5 Past   PTSD totals 
                              Week          - Sum of    
                                            subtotals   
                                            (B+C+D+E)   
      44  44                  44                      
       12               0               0               0
             0                                        
                                                              
Y                   Y       
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

JZP150-201            JZP150-201-1659-1006                    
16591006                                          
1659                  USA      1988-04-29          33  YEARS
<=65 years                                                 1
<=45 years                                                 1
F           2
WHITE                                               16591006/33/
                                                    F/W         
33/F             33/W/F      
Non-Hispanic or Latino                                      2
    63.9     165.1      24.3  2022-03-08  2022-03-08  2022-03-22
2022-06-13  2022-03-22  2022-06-29  Dummy Treatment B
B                     Dummy Treatment B  B                   
JZP150 4 mg           2  JZP150 4 mg           2  22MAR2022
13JUN2022  Y           Y                                 
Y           Y           Y         Y         Y          Y        
1988-04-29  Walter Duffy                   COMPLETED   
29JUN2022                                                    
              COMPLETED                                         
                                                          
N          N          N                        2
Absence                              2  No                 2
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

No                 2      1659         7         2  JZP150 4 mg 
       7       537  JZP150 4 mg           2  JZP150 4 mg 
        2        12  Week 12             12  Week 12     
      12  Week 12       PTSDTSEV 
PTSD total - Severity                                   22809
                          84  CAPS-5 Past   PTSD totals 
                              Week          - Sum of    
                                            subtotals   
                                            (B+C+D+E)   
      26  26                  44       -18    -40.9091
       12               0               0               0
             0                            < 30%       
                                          improvement 
                                          on the      
                                          CAPS-5 total
                                          score from  
                                          Baseline to 
                                          Week 12     
Y                                                             
Y                   Y       
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

Study Identifier      Unique Subject Identifier
Subject Identifier for the Study
Study Site                     Date/Time               Age
Identifier            Country  of Birth           Age  Units
                                                      Pooled
                                                         Age
                                                       Group
Pooled Age Group 1                                     1 (N)
                                                      Pooled
                                                         Age
                                                       Group
Pooled Age Group 2                                     2 (N)
Sex   Sex (N)
                                                    Subject
                                                    Identifier
                                                    for Study
Race                                                for Listing
Age/Sex          Age/Race/Sex
                                                    Ethnicity
Ethnicity                                                 (N)
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                    Baseline
                        Body  Date/Time               Date/Time
Baseline  Baseline      Mass  of             Date of  of First
  Weight    Height     Index  Informed      Informed  Study
    (kg)      (cm)  (kg/m^2)  Consent        Consent  Treatment
Date/Time   Subject     Subject
of Last     Reference   Reference
Study       Start       Stop        Description of
Treatment   Date/Time   Date/Time   Actual Arm
Description of        Description of     Description of
Actual Arm Code       Planned Arm        Planned Arm Code
                Planned                   Actual    Date of
Planned       Treatment  Actual        Treatment      First
Treatment           for  Treatment           for   Exposure
for Period       Period  for Period       Period         to
01               01 (N)  01               01 (N)  Treatment
  Date of
     Last
 Exposure  Safety      Enrolled    PK          PD
       to  Population  Population  Population  Population
Treatment  Flag        Flag        Flag        Flag
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                                  Modified  Completed  PTSD
RAND        Screened    Full      Full      Safety     Diagnosis
Population  Population  Analysis  Analysis  Follow-up  History
Flag        Flag        set Flag  Set       Flg        Flag
                                           Discon.
   Date of                                 Early from
 Birth (N)  Investigator Name              Study
  Discon.
    Early
     from
    Study
     Date  Reas. for Disc. Early from Study
Reas. for
Disc. Early
from Study,
Spcy.         Discon.  Early from study Trt.
              Reas. for
Reas. for     Early                                Subject
Disc. of      Discon. from  Date/Time     Date of  Death
Study Trt.    study Trt.    of Death        Death  Flag
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

           Completed
Completed  Efficacy                 Childbearing
Efficacy   Follow-up  Childbearing     Potential
Follow-up  at Week    Potential      for Females
at Week 4  12         for Females            (N)
                                        Subj on      Subj on
                           Concomitant  stable        stable
                                Use of  dose of      dose of
Concomitant Use              SSRI/SNRI  SSRI/SNRI  SSRI/SNRI
of SSRI/SNRI                       (N)  IRT          IRT (N)
Subj on      Subj on
stable        stable
dose of      dose of
SSRI/SNRI  SSRI/SNRI
EDC          EDC (N)      SITE    site_n      trtn  trt
          Analysis                  Planned
          Sequence  Planned       Treatment  Actual
 SITEIDN    Number  Treatment           (N)  Treatment
   Actual  Analysis
Treatment     Visit  Analysis         Visit
      (N)       (N)  Visit           Number  Visit
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

Analysis
  Window
   Visit  Analysis      Parameter
     (N)  Window Visit  Code
                                          Baseline
                                          Record    Analaysis
Parameter                                 Flag           Date
          Analysis  Analysis
Analysis     Date/  Relative  Parameter     Parameter
    Time      Time       Day  Category 1    Category 2
                                            Percentage
                                    Change      Change
Analysis  Analysis      Baseline      from        from
   Value  Value (C)        Value  Baseline    Baseline
 Duration
       of  Time-Dependent  Time-Dependent  Time-Dependent
Treatment       covariate       covariate       covariate
 in Weeks      for Week 1      for Week 4      for Week 8
                              Criterion
                              1
Time-Dependent                Evaluation
 covariate for  Analysis      Result      Analysis
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

       Week 12  Criterion 1   Flag        Criterion 2
Criterion                 Criterion                 Criterion
2                         3                         4
Evaluation                Evaluation                Evaluation
Result      Analysis      Result      Analysis      Result
Flag        Criterion 3   Flag        Criterion 4   Flag
Analysis  Analysis  Analysis
Record    Record    Record
Flag 01   Flag 02   Flag 03
ƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒ
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

JZP150-201            JZP150-201-1760-1002                    
17601002                                          
1760                  USA      1993-02-15          28  YEARS
<=65 years                                                 1
<=45 years                                                 1
F           2
BLACK OR AFRICAN AMERICAN                           17601002/28/
                                                    F/B         
28/F             28/B/F      
Non-Hispanic or Latino                                      2
   105.2     175.3      34.6  2022-01-07  2022-01-07  2022-01-22
2022-04-15  2022-01-22  2022-07-07  Dummy Treatment B
B                     Dummy Treatment B  B                   
JZP150 4 mg           2  JZP150 4 mg           2  22JAN2022
15APR2022  Y           Y                                 
Y           Y           Y         Y         N          Y        
1993-02-15  Donald J. Garcia               DISCONTINUED
07JUL2022  LOST TO FU                                        
LOST TO FU    COMPLETED                                         
                                                          
N          N          Y                        1
Absence                              2  No                 2
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

No                 2      1760         8         2  JZP150 4 mg 
       8       535  JZP150 4 mg           2  JZP150 4 mg 
        2         0  Baseline             0  Baseline    
       0  Baseline      PTSDTSEV 
PTSD total - Severity                     Y             22666
                          -1  CAPS-5 Past   PTSD totals 
                              Week          - Sum of    
                                            subtotals   
                                            (B+C+D+E)   
      38  38                  38                      
       12               0               0               0
             0                                        
                                                              
Y                   Y       
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

JZP150-201            JZP150-201-1760-1002                    
17601002                                          
1760                  USA      1993-02-15          28  YEARS
<=65 years                                                 1
<=45 years                                                 1
F           2
BLACK OR AFRICAN AMERICAN                           17601002/28/
                                                    F/B         
28/F             28/B/F      
Non-Hispanic or Latino                                      2
   105.2     175.3      34.6  2022-01-07  2022-01-07  2022-01-22
2022-04-15  2022-01-22  2022-07-07  Dummy Treatment B
B                     Dummy Treatment B  B                   
JZP150 4 mg           2  JZP150 4 mg           2  22JAN2022
15APR2022  Y           Y                                 
Y           Y           Y         Y         N          Y        
1993-02-15  Donald J. Garcia               DISCONTINUED
07JUL2022  LOST TO FU                                        
LOST TO FU    COMPLETED                                         
                                                          
N          N          Y                        1
Absence                              2  No                 2
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

No                 2      1760         8         2  JZP150 4 mg 
       8       537  JZP150 4 mg           2  JZP150 4 mg 
        2        12  Week 12             12  Week 12     
      12  Week 12       PTSDTSEV 
PTSD total - Severity                                   22750
                          84  CAPS-5 Past   PTSD totals 
                              Week          - Sum of    
                                            subtotals   
                                            (B+C+D+E)   
      12  12                  38       -26    -68.4211
       12               0               0               0
             0                            < 30%       
                                          improvement 
                                          on the      
                                          CAPS-5 total
                                          score from  
                                          Baseline to 
                                          Week 12     
Y                                                             
Y                   Y       
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

JZP150-201            JZP150-201-1760-1003                    
17601003                                          
1760                  USA      1989-09-22          32  YEARS
<=65 years                                                 1
<=45 years                                                 1
M           1
WHITE                                               17601003/32/
                                                    M/W         
32/M             32/W/M      
Non-Hispanic or Latino                                      2
   111.6     179.1      34.5  2022-01-12  2022-01-12  2022-01-22
2022-04-19  2022-01-22  2022-05-04  Dummy Treatment B
B                     Dummy Treatment B  B                   
JZP150 4 mg           2  JZP150 4 mg           2  22JAN2022
19APR2022  Y           Y                                 
Y           Y           Y         Y         Y          N        
1989-09-22  Donald J. Garcia               COMPLETED   
04MAY2022                                                    
              COMPLETED                                         
                                                          
N          N                                    
Presence                             1  Yes                1
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

Yes                1      1760         8         2  JZP150 4 mg 
       8       535  JZP150 4 mg           2  JZP150 4 mg 
        2         0  Baseline             0  Baseline    
       0  Baseline      PTSDTSEV 
PTSD total - Severity                     Y             22666
                          -1  CAPS-5 Past   PTSD totals 
                              Week          - Sum of    
                                            subtotals   
                                            (B+C+D+E)   
      46  46                  46                      
       13               0               0               0
             0                                        
                                                              
Y                   Y       
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

JZP150-201            JZP150-201-1760-1003                    
17601003                                          
1760                  USA      1989-09-22          32  YEARS
<=65 years                                                 1
<=45 years                                                 1
M           1
WHITE                                               17601003/32/
                                                    M/W         
32/M             32/W/M      
Non-Hispanic or Latino                                      2
   111.6     179.1      34.5  2022-01-12  2022-01-12  2022-01-22
2022-04-19  2022-01-22  2022-05-04  Dummy Treatment B
B                     Dummy Treatment B  B                   
JZP150 4 mg           2  JZP150 4 mg           2  22JAN2022
19APR2022  Y           Y                                 
Y           Y           Y         Y         Y          N        
1989-09-22  Donald J. Garcia               COMPLETED   
04MAY2022                                                    
              COMPLETED                                         
                                                          
N          N                                    
Presence                             1  Yes                1
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

Yes                1      1760         8         2  JZP150 4 mg 
       8       537  JZP150 4 mg           2  JZP150 4 mg 
        2        12  Week 12             12  Week 12     
      12  Week 12       PTSDTSEV 
PTSD total - Severity                                   22754
                          88  CAPS-5 Past   PTSD totals 
                              Week          - Sum of    
                                            subtotals   
                                            (B+C+D+E)   
      23  23                  46       -23         -50
       13               0               0               0
             0                            < 30%       
                                          improvement 
                                          on the      
                                          CAPS-5 total
                                          score from  
                                          Baseline to 
                                          Week 12     
Y                                                             
Y                   Y       
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

JZP150-201            JZP150-201-1760-1005                    
17601005                                          
1760                  USA      1972-12-02          49  YEARS
<=65 years                                                 1
>45 years                                                  2
F           2
WHITE                                               17601005/49/
                                                    F/W         
49/F             49/W/F      
Hispanic or Latino                                          1
    65.0     162.1      24.3  2022-02-07  2022-02-07  2022-03-01
2022-05-24  2022-03-01  2022-06-14  Dummy Treatment A
A                     Dummy Treatment A  A                   
JZP150 0.3            1  JZP150 0.3            1  01MAR2022
mg                       mg                                
24MAY2022  Y           Y                                 
Y           Y           Y         Y         Y          N        
1972-12-02  Donald J. Garcia               COMPLETED   
14JUN2022                                                    
              COMPLETED                                         
                                                          
N          N          Y                        1
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

Absence                              2  No                 2
No                 2      1760         8         1  JZP150 0.3  
                                                    mg          
       8       535  JZP150 0.3            1  JZP150 0.3  
                    mg                       mg          
        1         0  Baseline             0  Baseline    
       0  Baseline      PTSDTSEV 
PTSD total - Severity                     Y             22704
                          -1  CAPS-5 Past   PTSD totals 
                              Week          - Sum of    
                                            subtotals   
                                            (B+C+D+E)   
      34  34                  34                      
       12               0               0               0
             0                                        
                                                              
Y                   Y       
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

JZP150-201            JZP150-201-1760-1005                    
17601005                                          
1760                  USA      1972-12-02          49  YEARS
<=65 years                                                 1
>45 years                                                  2
F           2
WHITE                                               17601005/49/
                                                    F/W         
49/F             49/W/F      
Hispanic or Latino                                          1
    65.0     162.1      24.3  2022-02-07  2022-02-07  2022-03-01
2022-05-24  2022-03-01  2022-06-14  Dummy Treatment A
A                     Dummy Treatment A  A                   
JZP150 0.3            1  JZP150 0.3            1  01MAR2022
mg                       mg                                
24MAY2022  Y           Y                                 
Y           Y           Y         Y         Y          N        
1972-12-02  Donald J. Garcia               COMPLETED   
14JUN2022                                                    
              COMPLETED                                         
                                                          
N          N          Y                        1
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

Absence                              2  No                 2
No                 2      1760         8         1  JZP150 0.3  
                                                    mg          
       8       537  JZP150 0.3            1  JZP150 0.3  
                    mg                       mg          
        1        12  Week 12             12  Week 12     
      12  Week 12       PTSDTSEV 
PTSD total - Severity                                   22789
                          85  CAPS-5 Past   PTSD totals 
                              Week          - Sum of    
                                            subtotals   
                                            (B+C+D+E)   
      27  27                  34        -7    -20.5882
       12               0               0               0
             0                            < 30%       
                                          improvement 
                                          on the      
                                          CAPS-5 total
                                          score from  
                                          Baseline to 
                                          Week 12     
Y                                                             
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

Y                   Y       
JZP150-201            JZP150-201-1760-1007                    
17601007                                          
1760                  USA      1961-01-02          61  YEARS
<=65 years                                                 1
>45 years                                                  2
F           2
WHITE                                               17601007/61/
                                                    F/W         
61/F             61/W/F      
Non-Hispanic or Latino                                      2
    57.5     160.0      22.7  2022-03-11  2022-03-11  2022-03-25
2022-06-15  2022-03-25  2022-06-29  Dummy Treatment C
C                     Dummy Treatment C  C                   
Placebo               3  Placebo               3  25MAR2022
15JUN2022  Y           Y                                 
Y           Y           Y         Y         Y          N        
1961-01-02  Donald J. Garcia               COMPLETED   
29JUN2022                                                    
              COMPLETED                                         
                                                          
N          N                                    
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

Absence                              2  No                 2
No                 2      1760         8         3  Placebo     
       8       535  Placebo               3  Placebo     
        3         0  Baseline             0  Baseline    
       0  Baseline      PTSDTSEV 
PTSD total - Severity                     Y             22728
                          -1  CAPS-5 Past   PTSD totals 
                              Week          - Sum of    
                                            subtotals   
                                            (B+C+D+E)   
      37  37                  37                      
       12               0               0               0
             0                                        
                                                              
Y                   Y       
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

JZP150-201            JZP150-201-1760-1007                    
17601007                                          
1760                  USA      1961-01-02          61  YEARS
<=65 years                                                 1
>45 years                                                  2
F           2
WHITE                                               17601007/61/
                                                    F/W         
61/F             61/W/F      
Non-Hispanic or Latino                                      2
    57.5     160.0      22.7  2022-03-11  2022-03-11  2022-03-25
2022-06-15  2022-03-25  2022-06-29  Dummy Treatment C
C                     Dummy Treatment C  C                   
Placebo               3  Placebo               3  25MAR2022
15JUN2022  Y           Y                                 
Y           Y           Y         Y         Y          N        
1961-01-02  Donald J. Garcia               COMPLETED   
29JUN2022                                                    
              COMPLETED                                         
                                                          
N          N                                    
Absence                              2  No                 2
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

No                 2      1760         8         3  Placebo     
       8       537  Placebo               3  Placebo     
        3        12  Week 12             12  Week 12     
      12  Week 12       PTSDTSEV 
PTSD total - Severity                                   22811
                          83  CAPS-5 Past   PTSD totals 
                              Week          - Sum of    
                                            subtotals   
                                            (B+C+D+E)   
       2  2                   37       -35    -94.5946
       12               0               0               0
             0                            < 30%       
                                          improvement 
                                          on the      
                                          CAPS-5 total
                                          score from  
                                          Baseline to 
                                          Week 12     
Y                                                             
Y                   Y       
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

JZP150-201            JZP150-201-1760-1012                    
17601012                                          
1760                  USA      1977-04-28          45  YEARS
<=65 years                                                 1
<=45 years                                                 1
F           2
WHITE                                               17601012/45/
                                                    F/W         
45/F             45/W/F      
Non-Hispanic or Latino                                      2
    90.2     164.3      34.3  2022-05-05  2022-05-05  2022-05-27
2022-08-18  2022-05-27  2022-09-01  Dummy Treatment B
B                     Dummy Treatment B  B                   
JZP150 4 mg           2  JZP150 4 mg           2  27MAY2022
18AUG2022  Y           Y                                 
Y           Y           Y         Y         Y          Y        
1977-04-28  Donald J. Garcia               COMPLETED   
01SEP2022                                                    
              COMPLETED                                         
                                                          
N          N          N                        2
Absence                              2  No                 2
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

No                 2      1760         8         2  JZP150 4 mg 
       8       535  JZP150 4 mg           2  JZP150 4 mg 
        2         0  Baseline             0  Baseline    
       0  Baseline      PTSDTSEV 
PTSD total - Severity                     Y             22791
                          -1  CAPS-5 Past   PTSD totals 
                              Week          - Sum of    
                                            subtotals   
                                            (B+C+D+E)   
      42  42                  42                      
       12               0               0               0
             0                                        
                                                              
Y                   Y       
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

JZP150-201            JZP150-201-1760-1012                    
17601012                                          
1760                  USA      1977-04-28          45  YEARS
<=65 years                                                 1
<=45 years                                                 1
F           2
WHITE                                               17601012/45/
                                                    F/W         
45/F             45/W/F      
Non-Hispanic or Latino                                      2
    90.2     164.3      34.3  2022-05-05  2022-05-05  2022-05-27
2022-08-18  2022-05-27  2022-09-01  Dummy Treatment B
B                     Dummy Treatment B  B                   
JZP150 4 mg           2  JZP150 4 mg           2  27MAY2022
18AUG2022  Y           Y                                 
Y           Y           Y         Y         Y          Y        
1977-04-28  Donald J. Garcia               COMPLETED   
01SEP2022                                                    
              COMPLETED                                         
                                                          
N          N          N                        2
Absence                              2  No                 2
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

No                 2      1760         8         2  JZP150 4 mg 
       8       537  JZP150 4 mg           2  JZP150 4 mg 
        2        12  Week 12             12  Week 12     
      12  Week 12       PTSDTSEV 
PTSD total - Severity                                   22875
                          84  CAPS-5 Past   PTSD totals 
                              Week          - Sum of    
                                            subtotals   
                                            (B+C+D+E)   
       5  5                   42       -37    -88.0952
       12               0               0               0
             0                            < 30%       
                                          improvement 
                                          on the      
                                          CAPS-5 total
                                          score from  
                                          Baseline to 
                                          Week 12     
Y                                                             
Y                   Y       
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

JZP150-201            JZP150-201-1760-1014                    
17601014                                          
1760                  USA      1976-07-31          45  YEARS
<=65 years                                                 1
<=45 years                                                 1
F           2
WHITE                                               17601014/45/
                                                    F/W         
45/F             45/W/F      
Hispanic or Latino                                          1
    68.7     162.6      25.8  2022-05-19  2022-05-19  2022-06-08
2022-09-01  2022-06-08  2022-09-23  Dummy Treatment A
A                     Dummy Treatment A  A                   
JZP150 0.3            1  JZP150 0.3            1  08JUN2022
mg                       mg                                
01SEP2022  Y           Y                                 
Y           Y           Y         Y         Y          N        
1976-07-31  Donald J. Garcia               COMPLETED   
23SEP2022                                                    
              COMPLETED                                         
                                                          
N          N                                    
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

Absence                              2  No                 2
No                 2      1760         8         1  JZP150 0.3  
                                                    mg          
       8       535  JZP150 0.3            1  JZP150 0.3  
                    mg                       mg          
        1         0  Baseline             0  Baseline    
       0  Baseline      PTSDTSEV 
PTSD total - Severity                     Y             22803
                          -1  CAPS-5 Past   PTSD totals 
                              Week          - Sum of    
                                            subtotals   
                                            (B+C+D+E)   
      38  38                  38                      
       12               0               0               0
             0                                        
                                                              
Y                   Y       
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

JZP150-201            JZP150-201-1760-1014                    
17601014                                          
1760                  USA      1976-07-31          45  YEARS
<=65 years                                                 1
<=45 years                                                 1
F           2
WHITE                                               17601014/45/
                                                    F/W         
45/F             45/W/F      
Hispanic or Latino                                          1
    68.7     162.6      25.8  2022-05-19  2022-05-19  2022-06-08
2022-09-01  2022-06-08  2022-09-23  Dummy Treatment A
A                     Dummy Treatment A  A                   
JZP150 0.3            1  JZP150 0.3            1  08JUN2022
mg                       mg                                
01SEP2022  Y           Y                                 
Y           Y           Y         Y         Y          N        
1976-07-31  Donald J. Garcia               COMPLETED   
23SEP2022                                                    
              COMPLETED                                         
                                                          
N          N                                    
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

Absence                              2  No                 2
No                 2      1760         8         1  JZP150 0.3  
                                                    mg          
       8       537  JZP150 0.3            1  JZP150 0.3  
                    mg                       mg          
        1        12  Week 12             12  Week 12     
      12  Week 12       PTSDTSEV 
PTSD total - Severity                                   22889
                          86  CAPS-5 Past   PTSD totals 
                              Week          - Sum of    
                                            subtotals   
                                            (B+C+D+E)   
       7  7                   38       -31    -81.5789
       12               0               0               0
             0                            < 30%       
                                          improvement 
                                          on the      
                                          CAPS-5 total
                                          score from  
                                          Baseline to 
                                          Week 12     
Y                                                             
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

Y                   Y       
JZP150-201            JZP150-201-1760-1022                    
17601022                                          
1760                  USA      1985-04-10          37  YEARS
<=65 years                                                 1
<=45 years                                                 1
F           2
MULTIPLE                                            17601022/37/
                                                    F/MU: A, W  
37/F             37/MU: A,   
                 W/F         
Non-Hispanic or Latino                                      2
    95.3     165.9      34.7  2022-08-12  2022-08-12  2022-09-09
2022-11-06  2022-09-09  2022-11-06  Dummy Treatment B
B                     Dummy Treatment B  B                   
JZP150 4 mg           2  JZP150 4 mg           2  09SEP2022
06NOV2022  Y           Y                                 
Y           Y           Y         Y         N          Y        
1985-04-10  Donald J. Garcia               ONGOING     
                                                             
              ONGOING                                           
                                                          
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

N          N          Y                        1
Absence                              2  No                 2
No                 2      1760         8         2  JZP150 4 mg 
       8       357  JZP150 4 mg           2  JZP150 4 mg 
        2         0  Baseline             0  Baseline    
       0  Baseline      PTSDTSEV 
PTSD total - Severity                                   22897
                           1  CAPS-5 Past   PTSD totals 
                              Week          - Sum of    
                                            subtotals   
                                            (B+C+D+E)   
      33  33                                          
        8               0               0               0
             1                                        
                                                              
Y                   Y       
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

JZP150-201            JZP150-201-1760-1025                    
17601025                                          
1760                  USA      1998-02-03          24  YEARS
<=65 years                                                 1
<=45 years                                                 1
F           2
WHITE                                               17601025/24/
                                                    F/W         
24/F             24/W/F      
Non-Hispanic or Latino                                      2
    74.2     160.8      28.4  2022-09-01  2022-09-01  2022-09-14
2022-10-22  2022-09-14  2022-10-22  Dummy Treatment B
B                     Dummy Treatment B  B                   
JZP150 4 mg           2  JZP150 4 mg           2  14SEP2022
22OCT2022  Y           Y                                 
Y           Y           Y         Y         N          Y        
1998-02-03  Donald J. Garcia               ONGOING     
                                                             
              DISCONTINUED                                      
WITHDRAWAL    WITHDRAWAL                                  
OF CONSENT    OF CONSENT                                  
BY STUDY      BY STUDY                                    
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

PARTICIPANT   PARTICIPANT                                 
N          N          Y                        1
Presence                             1  Yes                1
Yes                1      1760         8         2  JZP150 4 mg 
       8       535  JZP150 4 mg           2  JZP150 4 mg 
        2         0  Baseline             0  Baseline    
       0  Baseline      PTSDTSEV 
PTSD total - Severity                     Y             22901
                          -1  CAPS-5 Past   PTSD totals 
                              Week          - Sum of    
                                            subtotals   
                                            (B+C+D+E)   
      18  18                  18                      
        6               0               0               1
             1                                        
                                                              
Y                   Y       
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

JZP150-201            JZP150-201-1760-1025                    
17601025                                          
1760                  USA      1998-02-03          24  YEARS
<=65 years                                                 1
<=45 years                                                 1
F           2
WHITE                                               17601025/24/
                                                    F/W         
24/F             24/W/F      
Non-Hispanic or Latino                                      2
    74.2     160.8      28.4  2022-09-01  2022-09-01  2022-09-14
2022-10-22  2022-09-14  2022-10-22  Dummy Treatment B
B                     Dummy Treatment B  B                   
JZP150 4 mg           2  JZP150 4 mg           2  14SEP2022
22OCT2022  Y           Y                                 
Y           Y           Y         Y         N          Y        
1998-02-03  Donald J. Garcia               ONGOING     
                                                             
              DISCONTINUED                                      
WITHDRAWAL    WITHDRAWAL                                  
OF CONSENT    OF CONSENT                                  
BY STUDY      BY STUDY                                    
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

PARTICIPANT   PARTICIPANT                                 
N          N          Y                        1
Presence                             1  Yes                1
Yes                1      1760         8         2  JZP150 4 mg 
       8       537  JZP150 4 mg           2  JZP150 4 mg 
        2        12  Week 12             12  Week 12     
      12  Week 12       PTSDTSEV 
PTSD total - Severity                                   22943
                          42  CAPS-5 Past   PTSD totals 
                              Week          - Sum of    
                                            subtotals   
                                            (B+C+D+E)   
       6  6                   18       -12    -66.6667
        6               0               0               1
             1                            < 30%       
                                          improvement 
                                          on the      
                                          CAPS-5 total
                                          score from  
                                          Baseline to 
                                          Week 12     
Y                                                             
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

Y                   Y       
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

Study Identifier      Unique Subject Identifier
Subject Identifier for the Study
Study Site                     Date/Time               Age
Identifier            Country  of Birth           Age  Units
                                                      Pooled
                                                         Age
                                                       Group
Pooled Age Group 1                                     1 (N)
                                                      Pooled
                                                         Age
                                                       Group
Pooled Age Group 2                                     2 (N)
Sex   Sex (N)
                                                    Subject
                                                    Identifier
                                                    for Study
Race                                                for Listing
Age/Sex          Age/Race/Sex
                                                    Ethnicity
Ethnicity                                                 (N)
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                    Baseline
                        Body  Date/Time               Date/Time
Baseline  Baseline      Mass  of             Date of  of First
  Weight    Height     Index  Informed      Informed  Study
    (kg)      (cm)  (kg/m^2)  Consent        Consent  Treatment
Date/Time   Subject     Subject
of Last     Reference   Reference
Study       Start       Stop        Description of
Treatment   Date/Time   Date/Time   Actual Arm
Description of        Description of     Description of
Actual Arm Code       Planned Arm        Planned Arm Code
                Planned                   Actual    Date of
Planned       Treatment  Actual        Treatment      First
Treatment           for  Treatment           for   Exposure
for Period       Period  for Period       Period         to
01               01 (N)  01               01 (N)  Treatment
  Date of
     Last
 Exposure  Safety      Enrolled    PK          PD
       to  Population  Population  Population  Population
Treatment  Flag        Flag        Flag        Flag
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                                  Modified  Completed  PTSD
RAND        Screened    Full      Full      Safety     Diagnosis
Population  Population  Analysis  Analysis  Follow-up  History
Flag        Flag        set Flag  Set       Flg        Flag
                                           Discon.
   Date of                                 Early from
 Birth (N)  Investigator Name              Study
  Discon.
    Early
     from
    Study
     Date  Reas. for Disc. Early from Study
Reas. for
Disc. Early
from Study,
Spcy.         Discon.  Early from study Trt.
              Reas. for
Reas. for     Early                                Subject
Disc. of      Discon. from  Date/Time     Date of  Death
Study Trt.    study Trt.    of Death        Death  Flag
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

           Completed
Completed  Efficacy                 Childbearing
Efficacy   Follow-up  Childbearing     Potential
Follow-up  at Week    Potential      for Females
at Week 4  12         for Females            (N)
                                        Subj on      Subj on
                           Concomitant  stable        stable
                                Use of  dose of      dose of
Concomitant Use              SSRI/SNRI  SSRI/SNRI  SSRI/SNRI
of SSRI/SNRI                       (N)  IRT          IRT (N)
Subj on      Subj on
stable        stable
dose of      dose of
SSRI/SNRI  SSRI/SNRI
EDC          EDC (N)      SITE    site_n      trtn  trt
          Analysis                  Planned
          Sequence  Planned       Treatment  Actual
 SITEIDN    Number  Treatment           (N)  Treatment
   Actual  Analysis
Treatment     Visit  Analysis         Visit
      (N)       (N)  Visit           Number  Visit
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

Analysis
  Window
   Visit  Analysis      Parameter
     (N)  Window Visit  Code
                                          Baseline
                                          Record    Analaysis
Parameter                                 Flag           Date
          Analysis  Analysis
Analysis     Date/  Relative  Parameter     Parameter
    Time      Time       Day  Category 1    Category 2
                                            Percentage
                                    Change      Change
Analysis  Analysis      Baseline      from        from
   Value  Value (C)        Value  Baseline    Baseline
 Duration
       of  Time-Dependent  Time-Dependent  Time-Dependent
Treatment       covariate       covariate       covariate
 in Weeks      for Week 1      for Week 4      for Week 8
                              Criterion
                              1
Time-Dependent                Evaluation
 covariate for  Analysis      Result      Analysis
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

       Week 12  Criterion 1   Flag        Criterion 2
Criterion                 Criterion                 Criterion
2                         3                         4
Evaluation                Evaluation                Evaluation
Result      Analysis      Result      Analysis      Result
Flag        Criterion 3   Flag        Criterion 4   Flag
Analysis  Analysis  Analysis
Record    Record    Record
Flag 01   Flag 02   Flag 03
ƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒ
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

JZP150-201            JZP150-201-1766-1002                    
17661002                                          
1766                  USA      1971-01-01          51  YEARS
<=65 years                                                 1
>45 years                                                  2
F           2
WHITE                                               17661002/51/
                                                    F/W         
51/F             51/W/F      
Non-Hispanic or Latino                                      2
   108.1     177.8      34.4  2022-06-23  2022-06-23  2022-07-15
2022-10-06  2022-07-15  2022-10-20  Dummy Treatment B
B                     Dummy Treatment B  B                   
JZP150 4 mg           2  JZP150 4 mg           2  15JUL2022
06OCT2022  Y           Y                                 
Y           Y           Y         Y         Y          N        
1971-01-01  Benny L. Barnhart, MD          COMPLETED   
20OCT2022                                                    
              COMPLETED                                         
                                                          
N          N          N                        2
Absence                              2  No                 2
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

No                 2      1766         9         2  JZP150 4 mg 
       9       357  JZP150 4 mg           2  JZP150 4 mg 
        2         0  Baseline             0  Baseline    
       0  Baseline      PTSDTSEV 
PTSD total - Severity                     Y             22840
                          -1  CAPS-5 Past   PTSD totals 
                              Week          - Sum of    
                                            subtotals   
                                            (B+C+D+E)   
      42  42                  42                      
       12               0               0               0
             0                                        
                                                              
Y                   Y       
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

JZP150-201            JZP150-201-1766-1002                    
17661002                                          
1766                  USA      1971-01-01          51  YEARS
<=65 years                                                 1
>45 years                                                  2
F           2
WHITE                                               17661002/51/
                                                    F/W         
51/F             51/W/F      
Non-Hispanic or Latino                                      2
   108.1     177.8      34.4  2022-06-23  2022-06-23  2022-07-15
2022-10-06  2022-07-15  2022-10-20  Dummy Treatment B
B                     Dummy Treatment B  B                   
JZP150 4 mg           2  JZP150 4 mg           2  15JUL2022
06OCT2022  Y           Y                                 
Y           Y           Y         Y         Y          N        
1971-01-01  Benny L. Barnhart, MD          COMPLETED   
20OCT2022                                                    
              COMPLETED                                         
                                                          
N          N          N                        2
Absence                              2  No                 2
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

No                 2      1766         9         2  JZP150 4 mg 
       9       358  JZP150 4 mg           2  JZP150 4 mg 
        2        12  Week 12             12  Week 12     
      12  Week 12       PTSDTSEV 
PTSD total - Severity                                   22924
                          84  CAPS-5 Past   PTSD totals 
                              Week          - Sum of    
                                            subtotals   
                                            (B+C+D+E)   
      33  33                  42        -9    -21.4286
       12               0               0               0
             0                            < 30%       
                                          improvement 
                                          on the      
                                          CAPS-5 total
                                          score from  
                                          Baseline to 
                                          Week 12     
Y                                                             
Y                   Y       
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

JZP150-201            JZP150-201-1766-1004                    
17661004                                          
1766                  USA      1987-04-03          35  YEARS
<=65 years                                                 1
<=45 years                                                 1
F           2
WHITE                                               17661004/35/
                                                    F/W         
35/F             35/W/F      
Non-Hispanic or Latino                                      2
    85.6     167.6      30.0  2022-07-07  2022-07-07  2022-07-22
2022-10-13  2022-07-22  2022-10-27  Dummy Treatment C
C                     Dummy Treatment C  C                   
Placebo               3  Placebo               3  22JUL2022
13OCT2022  Y           Y                                 
Y           Y           Y         Y         Y          N        
1987-04-03  Benny L. Barnhart, MD          COMPLETED   
27OCT2022                                                    
              COMPLETED                                         
                                                          
N          N          Y                        1
Absence                              2  No                 2
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

No                 2      1766         9         3  Placebo     
       9       714  Placebo               3  Placebo     
        3         0  Baseline             0  Baseline    
       0  Baseline      PTSDTSEV 
PTSD total - Severity                     Y             22847
                          -1  CAPS-5 Past   PTSD totals 
                              Week          - Sum of    
                                            subtotals   
                                            (B+C+D+E)   
      42  42                  42                      
       12               0               0               0
             0                                        
                                                              
Y                   Y       
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

JZP150-201            JZP150-201-1766-1004                    
17661004                                          
1766                  USA      1987-04-03          35  YEARS
<=65 years                                                 1
<=45 years                                                 1
F           2
WHITE                                               17661004/35/
                                                    F/W         
35/F             35/W/F      
Non-Hispanic or Latino                                      2
    85.6     167.6      30.0  2022-07-07  2022-07-07  2022-07-22
2022-10-13  2022-07-22  2022-10-27  Dummy Treatment C
C                     Dummy Treatment C  C                   
Placebo               3  Placebo               3  22JUL2022
13OCT2022  Y           Y                                 
Y           Y           Y         Y         Y          N        
1987-04-03  Benny L. Barnhart, MD          COMPLETED   
27OCT2022                                                    
              COMPLETED                                         
                                                          
N          N          Y                        1
Absence                              2  No                 2
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

No                 2      1766         9         3  Placebo     
       9       716  Placebo               3  Placebo     
        3        12  Week 12             12  Week 12     
      12  Week 12       PTSDTSEV 
PTSD total - Severity                                   22931
                          84  CAPS-5 Past   PTSD totals 
                              Week          - Sum of    
                                            subtotals   
                                            (B+C+D+E)   
       0  0                   42       -42        -100
       12               0               0               0
             0                            < 30%       
                                          improvement 
                                          on the      
                                          CAPS-5 total
                                          score from  
                                          Baseline to 
                                          Week 12     
Y                                                             
Y                   Y       
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

JZP150-201            JZP150-201-1766-1006                    
17661006                                          
1766                  USA      1986-07-22          36  YEARS
<=65 years                                                 1
<=45 years                                                 1
F           2
WHITE                                               17661006/36/
                                                    F/W         
36/F             36/W/F      
Non-Hispanic or Latino                                      2
    79.5     160.0      30.6  2022-09-22  2022-09-22  2022-10-14
2022-11-06  2022-10-14  2022-11-06  Dummy Treatment B
B                     Dummy Treatment B  B                   
JZP150 4 mg           2  JZP150 4 mg           2  14OCT2022
06NOV2022  Y           Y                                 
Y           Y           Y         Y         N          Y        
1986-07-22  Benny L. Barnhart, MD          ONGOING     
                                                             
              ONGOING                                           
                                                          
N          N          Y                        1
Absence                              2  No                 2
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

No                 2      1766         9         2  JZP150 4 mg 
       9       179  JZP150 4 mg           2  JZP150 4 mg 
        2         0  Baseline             0  Baseline    
       0  Baseline      PTSDTSEV 
PTSD total - Severity                     Y             22931
                          -1  CAPS-5 Past   PTSD totals 
                              Week          - Sum of    
                                            subtotals   
                                            (B+C+D+E)   
      24  24                  24                      
        3               0               1               2
             2                                        
                                                              
Y                   Y       
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

Study Identifier      Unique Subject Identifier
Subject Identifier for the Study
Study Site                     Date/Time               Age
Identifier            Country  of Birth           Age  Units
                                                      Pooled
                                                         Age
                                                       Group
Pooled Age Group 1                                     1 (N)
                                                      Pooled
                                                         Age
                                                       Group
Pooled Age Group 2                                     2 (N)
Sex   Sex (N)
                                                    Subject
                                                    Identifier
                                                    for Study
Race                                                for Listing
Age/Sex          Age/Race/Sex
                                                    Ethnicity
Ethnicity                                                 (N)
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                    Baseline
                        Body  Date/Time               Date/Time
Baseline  Baseline      Mass  of             Date of  of First
  Weight    Height     Index  Informed      Informed  Study
    (kg)      (cm)  (kg/m^2)  Consent        Consent  Treatment
Date/Time   Subject     Subject
of Last     Reference   Reference
Study       Start       Stop        Description of
Treatment   Date/Time   Date/Time   Actual Arm
Description of        Description of     Description of
Actual Arm Code       Planned Arm        Planned Arm Code
                Planned                   Actual    Date of
Planned       Treatment  Actual        Treatment      First
Treatment           for  Treatment           for   Exposure
for Period       Period  for Period       Period         to
01               01 (N)  01               01 (N)  Treatment
  Date of
     Last
 Exposure  Safety      Enrolled    PK          PD
       to  Population  Population  Population  Population
Treatment  Flag        Flag        Flag        Flag
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                                  Modified  Completed  PTSD
RAND        Screened    Full      Full      Safety     Diagnosis
Population  Population  Analysis  Analysis  Follow-up  History
Flag        Flag        set Flag  Set       Flg        Flag
                                           Discon.
   Date of                                 Early from
 Birth (N)  Investigator Name              Study
  Discon.
    Early
     from
    Study
     Date  Reas. for Disc. Early from Study
Reas. for
Disc. Early
from Study,
Spcy.         Discon.  Early from study Trt.
              Reas. for
Reas. for     Early                                Subject
Disc. of      Discon. from  Date/Time     Date of  Death
Study Trt.    study Trt.    of Death        Death  Flag
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

           Completed
Completed  Efficacy                 Childbearing
Efficacy   Follow-up  Childbearing     Potential
Follow-up  at Week    Potential      for Females
at Week 4  12         for Females            (N)
                                        Subj on      Subj on
                           Concomitant  stable        stable
                                Use of  dose of      dose of
Concomitant Use              SSRI/SNRI  SSRI/SNRI  SSRI/SNRI
of SSRI/SNRI                       (N)  IRT          IRT (N)
Subj on      Subj on
stable        stable
dose of      dose of
SSRI/SNRI  SSRI/SNRI
EDC          EDC (N)      SITE    site_n      trtn  trt
          Analysis                  Planned
          Sequence  Planned       Treatment  Actual
 SITEIDN    Number  Treatment           (N)  Treatment
   Actual  Analysis
Treatment     Visit  Analysis         Visit
      (N)       (N)  Visit           Number  Visit
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

Analysis
  Window
   Visit  Analysis      Parameter
     (N)  Window Visit  Code
                                          Baseline
                                          Record    Analaysis
Parameter                                 Flag           Date
          Analysis  Analysis
Analysis     Date/  Relative  Parameter     Parameter
    Time      Time       Day  Category 1    Category 2
                                            Percentage
                                    Change      Change
Analysis  Analysis      Baseline      from        from
   Value  Value (C)        Value  Baseline    Baseline
 Duration
       of  Time-Dependent  Time-Dependent  Time-Dependent
Treatment       covariate       covariate       covariate
 in Weeks      for Week 1      for Week 4      for Week 8
                              Criterion
                              1
Time-Dependent                Evaluation
 covariate for  Analysis      Result      Analysis
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

       Week 12  Criterion 1   Flag        Criterion 2
Criterion                 Criterion                 Criterion
2                         3                         4
Evaluation                Evaluation                Evaluation
Result      Analysis      Result      Analysis      Result
Flag        Criterion 3   Flag        Criterion 4   Flag
Analysis  Analysis  Analysis
Record    Record    Record
Flag 01   Flag 02   Flag 03
ƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒ
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

JZP150-201            JZP150-201-1768-1001                    
17681001                                          
1768                  USA      1973-05-07          49  YEARS
<=65 years                                                 1
>45 years                                                  2
F           2
BLACK OR AFRICAN AMERICAN                           17681001/49/
                                                    F/B         
49/F             49/B/F      
Non-Hispanic or Latino                                      2
   108.9     180.0      33.6  2022-07-29  2022-07-29  2022-08-25
2022-11-06  2022-08-25  2022-11-06  Dummy Treatment C
C                     Dummy Treatment C  C                   
Placebo               3  Placebo               3  25AUG2022
06NOV2022  Y           Y                                 
Y           Y           Y         Y         N          N        
1973-05-07  Scott Bartley                  ONGOING     
                                                             
              ONGOING                                           
                                                          
N          N          N                        2
Presence                             1  Yes                1
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

Yes                1      1768        10         3  Placebo     
      10       357  Placebo               3  Placebo     
        3         0  Baseline             0  Baseline    
       0  Baseline      PTSDTSEV 
PTSD total - Severity                                   22882
                           1  CAPS-5 Past   PTSD totals 
                              Week          - Sum of    
                                            subtotals   
                                            (B+C+D+E)   
      31  31                                          
       11               0               0               0
             0                                        
                                                              
Y                   Y       
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

Study Identifier      Unique Subject Identifier
Subject Identifier for the Study
Study Site                     Date/Time               Age
Identifier            Country  of Birth           Age  Units
                                                      Pooled
                                                         Age
                                                       Group
Pooled Age Group 1                                     1 (N)
                                                      Pooled
                                                         Age
                                                       Group
Pooled Age Group 2                                     2 (N)
Sex   Sex (N)
                                                    Subject
                                                    Identifier
                                                    for Study
Race                                                for Listing
Age/Sex          Age/Race/Sex
                                                    Ethnicity
Ethnicity                                                 (N)
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                    Baseline
                        Body  Date/Time               Date/Time
Baseline  Baseline      Mass  of             Date of  of First
  Weight    Height     Index  Informed      Informed  Study
    (kg)      (cm)  (kg/m^2)  Consent        Consent  Treatment
Date/Time   Subject     Subject
of Last     Reference   Reference
Study       Start       Stop        Description of
Treatment   Date/Time   Date/Time   Actual Arm
Description of        Description of     Description of
Actual Arm Code       Planned Arm        Planned Arm Code
                Planned                   Actual    Date of
Planned       Treatment  Actual        Treatment      First
Treatment           for  Treatment           for   Exposure
for Period       Period  for Period       Period         to
01               01 (N)  01               01 (N)  Treatment
  Date of
     Last
 Exposure  Safety      Enrolled    PK          PD
       to  Population  Population  Population  Population
Treatment  Flag        Flag        Flag        Flag
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                                  Modified  Completed  PTSD
RAND        Screened    Full      Full      Safety     Diagnosis
Population  Population  Analysis  Analysis  Follow-up  History
Flag        Flag        set Flag  Set       Flg        Flag
                                           Discon.
   Date of                                 Early from
 Birth (N)  Investigator Name              Study
  Discon.
    Early
     from
    Study
     Date  Reas. for Disc. Early from Study
Reas. for
Disc. Early
from Study,
Spcy.         Discon.  Early from study Trt.
              Reas. for
Reas. for     Early                                Subject
Disc. of      Discon. from  Date/Time     Date of  Death
Study Trt.    study Trt.    of Death        Death  Flag
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

           Completed
Completed  Efficacy                 Childbearing
Efficacy   Follow-up  Childbearing     Potential
Follow-up  at Week    Potential      for Females
at Week 4  12         for Females            (N)
                                        Subj on      Subj on
                           Concomitant  stable        stable
                                Use of  dose of      dose of
Concomitant Use              SSRI/SNRI  SSRI/SNRI  SSRI/SNRI
of SSRI/SNRI                       (N)  IRT          IRT (N)
Subj on      Subj on
stable        stable
dose of      dose of
SSRI/SNRI  SSRI/SNRI
EDC          EDC (N)      SITE    site_n      trtn  trt
          Analysis                  Planned
          Sequence  Planned       Treatment  Actual
 SITEIDN    Number  Treatment           (N)  Treatment
   Actual  Analysis
Treatment     Visit  Analysis         Visit
      (N)       (N)  Visit           Number  Visit
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

Analysis
  Window
   Visit  Analysis      Parameter
     (N)  Window Visit  Code
                                          Baseline
                                          Record    Analaysis
Parameter                                 Flag           Date
          Analysis  Analysis
Analysis     Date/  Relative  Parameter     Parameter
    Time      Time       Day  Category 1    Category 2
                                            Percentage
                                    Change      Change
Analysis  Analysis      Baseline      from        from
   Value  Value (C)        Value  Baseline    Baseline
 Duration
       of  Time-Dependent  Time-Dependent  Time-Dependent
Treatment       covariate       covariate       covariate
 in Weeks      for Week 1      for Week 4      for Week 8
                              Criterion
                              1
Time-Dependent                Evaluation
 covariate for  Analysis      Result      Analysis
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

       Week 12  Criterion 1   Flag        Criterion 2
Criterion                 Criterion                 Criterion
2                         3                         4
Evaluation                Evaluation                Evaluation
Result      Analysis      Result      Analysis      Result
Flag        Criterion 3   Flag        Criterion 4   Flag
Analysis  Analysis  Analysis
Record    Record    Record
Flag 01   Flag 02   Flag 03
ƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒ
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

JZP150-201            JZP150-201-1861-1001                    
18611001                                          
1861                  USA      1986-10-04          35  YEARS
<=65 years                                                 1
<=45 years                                                 1
F           2
WHITE                                               18611001/35/
                                                    F/W         
35/F             35/W/F      
Hispanic or Latino                                          1
    95.0     166.5      34.3  2022-08-15  2022-08-15  2022-08-31
2022-11-06  2022-08-31  2022-11-06  Dummy Treatment B
B                     Dummy Treatment B  B                   
JZP150 4 mg           2  JZP150 4 mg           2  31AUG2022
06NOV2022  Y           Y                                 
Y           Y           Y         Y         N          N        
1986-10-04  Jelena Kunovac                 ONGOING     
                                                             
              ONGOING                                           
                                                          
N          N          Y                        1
Absence                              2  No                 2
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

No                 2      1861        11         2  JZP150 4 mg 
      11       357  JZP150 4 mg           2  JZP150 4 mg 
        2         0  Baseline             0  Baseline    
       0  Baseline      PTSDTSEV 
PTSD total - Severity                                   22888
                           1  CAPS-5 Past   PTSD totals 
                              Week          - Sum of    
                                            subtotals   
                                            (B+C+D+E)   
      40  40                                          
       10               0               0               0
             1                                        
                                                              
Y                   Y       
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

Study Identifier      Unique Subject Identifier
Subject Identifier for the Study
Study Site                     Date/Time               Age
Identifier            Country  of Birth           Age  Units
                                                      Pooled
                                                         Age
                                                       Group
Pooled Age Group 1                                     1 (N)
                                                      Pooled
                                                         Age
                                                       Group
Pooled Age Group 2                                     2 (N)
Sex   Sex (N)
                                                    Subject
                                                    Identifier
                                                    for Study
Race                                                for Listing
Age/Sex          Age/Race/Sex
                                                    Ethnicity
Ethnicity                                                 (N)
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                    Baseline
                        Body  Date/Time               Date/Time
Baseline  Baseline      Mass  of             Date of  of First
  Weight    Height     Index  Informed      Informed  Study
    (kg)      (cm)  (kg/m^2)  Consent        Consent  Treatment
Date/Time   Subject     Subject
of Last     Reference   Reference
Study       Start       Stop        Description of
Treatment   Date/Time   Date/Time   Actual Arm
Description of        Description of     Description of
Actual Arm Code       Planned Arm        Planned Arm Code
                Planned                   Actual    Date of
Planned       Treatment  Actual        Treatment      First
Treatment           for  Treatment           for   Exposure
for Period       Period  for Period       Period         to
01               01 (N)  01               01 (N)  Treatment
  Date of
     Last
 Exposure  Safety      Enrolled    PK          PD
       to  Population  Population  Population  Population
Treatment  Flag        Flag        Flag        Flag
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                                  Modified  Completed  PTSD
RAND        Screened    Full      Full      Safety     Diagnosis
Population  Population  Analysis  Analysis  Follow-up  History
Flag        Flag        set Flag  Set       Flg        Flag
                                           Discon.
   Date of                                 Early from
 Birth (N)  Investigator Name              Study
  Discon.
    Early
     from
    Study
     Date  Reas. for Disc. Early from Study
Reas. for
Disc. Early
from Study,
Spcy.         Discon.  Early from study Trt.
              Reas. for
Reas. for     Early                                Subject
Disc. of      Discon. from  Date/Time     Date of  Death
Study Trt.    study Trt.    of Death        Death  Flag
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

           Completed
Completed  Efficacy                 Childbearing
Efficacy   Follow-up  Childbearing     Potential
Follow-up  at Week    Potential      for Females
at Week 4  12         for Females            (N)
                                        Subj on      Subj on
                           Concomitant  stable        stable
                                Use of  dose of      dose of
Concomitant Use              SSRI/SNRI  SSRI/SNRI  SSRI/SNRI
of SSRI/SNRI                       (N)  IRT          IRT (N)
Subj on      Subj on
stable        stable
dose of      dose of
SSRI/SNRI  SSRI/SNRI
EDC          EDC (N)      SITE    site_n      trtn  trt
          Analysis                  Planned
          Sequence  Planned       Treatment  Actual
 SITEIDN    Number  Treatment           (N)  Treatment
   Actual  Analysis
Treatment     Visit  Analysis         Visit
      (N)       (N)  Visit           Number  Visit
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

Analysis
  Window
   Visit  Analysis      Parameter
     (N)  Window Visit  Code
                                          Baseline
                                          Record    Analaysis
Parameter                                 Flag           Date
          Analysis  Analysis
Analysis     Date/  Relative  Parameter     Parameter
    Time      Time       Day  Category 1    Category 2
                                            Percentage
                                    Change      Change
Analysis  Analysis      Baseline      from        from
   Value  Value (C)        Value  Baseline    Baseline
 Duration
       of  Time-Dependent  Time-Dependent  Time-Dependent
Treatment       covariate       covariate       covariate
 in Weeks      for Week 1      for Week 4      for Week 8
                              Criterion
                              1
Time-Dependent                Evaluation
 covariate for  Analysis      Result      Analysis
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

       Week 12  Criterion 1   Flag        Criterion 2
Criterion                 Criterion                 Criterion
2                         3                         4
Evaluation                Evaluation                Evaluation
Result      Analysis      Result      Analysis      Result
Flag        Criterion 3   Flag        Criterion 4   Flag
Analysis  Analysis  Analysis
Record    Record    Record
Flag 01   Flag 02   Flag 03
ƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒ
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

JZP150-201            JZP150-201-1969-1001                    
19691001                                          
1969                  USA      1994-06-30          28  YEARS
<=65 years                                                 1
<=45 years                                                 1
F           2
WHITE                                               19691001/28/
                                                    F/W         
28/F             28/W/F      
Hispanic or Latino                                          1
    71.5     161.1      27.8  2022-09-13  2022-09-13  2022-10-12
2022-11-06  2022-10-12  2022-11-06  Dummy Treatment B
B                     Dummy Treatment B  B                   
JZP150 4 mg           2  JZP150 4 mg           2  12OCT2022
06NOV2022  Y           Y                                 
Y           Y           Y         Y         N          N        
1994-06-30  Tony Ortiz, PhD                ONGOING     
                                                             
              ONGOING                                           
                                                          
N          N          Y                        1
Absence                              2  No                 2
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

No                 2      1969        12         2  JZP150 4 mg 
      12       179  JZP150 4 mg           2  JZP150 4 mg 
        2         0  Baseline             0  Baseline    
       0  Baseline      PTSDTSEV 
PTSD total - Severity                     Y             22929
                          -1  CAPS-5 Past   PTSD totals 
                              Week          - Sum of    
                                            subtotals   
                                            (B+C+D+E)   
      33  33                  33                      
        4               0               0               1
             2                                        
                                                              
Y                   Y       
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

Study Identifier      Unique Subject Identifier
Subject Identifier for the Study
Study Site                     Date/Time               Age
Identifier            Country  of Birth           Age  Units
                                                      Pooled
                                                         Age
                                                       Group
Pooled Age Group 1                                     1 (N)
                                                      Pooled
                                                         Age
                                                       Group
Pooled Age Group 2                                     2 (N)
Sex   Sex (N)
                                                    Subject
                                                    Identifier
                                                    for Study
Race                                                for Listing
Age/Sex          Age/Race/Sex
                                                    Ethnicity
Ethnicity                                                 (N)
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                    Baseline
                        Body  Date/Time               Date/Time
Baseline  Baseline      Mass  of             Date of  of First
  Weight    Height     Index  Informed      Informed  Study
    (kg)      (cm)  (kg/m^2)  Consent        Consent  Treatment
Date/Time   Subject     Subject
of Last     Reference   Reference
Study       Start       Stop        Description of
Treatment   Date/Time   Date/Time   Actual Arm
Description of        Description of     Description of
Actual Arm Code       Planned Arm        Planned Arm Code
                Planned                   Actual    Date of
Planned       Treatment  Actual        Treatment      First
Treatment           for  Treatment           for   Exposure
for Period       Period  for Period       Period         to
01               01 (N)  01               01 (N)  Treatment
  Date of
     Last
 Exposure  Safety      Enrolled    PK          PD
       to  Population  Population  Population  Population
Treatment  Flag        Flag        Flag        Flag
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                                  Modified  Completed  PTSD
RAND        Screened    Full      Full      Safety     Diagnosis
Population  Population  Analysis  Analysis  Follow-up  History
Flag        Flag        set Flag  Set       Flg        Flag
                                           Discon.
   Date of                                 Early from
 Birth (N)  Investigator Name              Study
  Discon.
    Early
     from
    Study
     Date  Reas. for Disc. Early from Study
Reas. for
Disc. Early
from Study,
Spcy.         Discon.  Early from study Trt.
              Reas. for
Reas. for     Early                                Subject
Disc. of      Discon. from  Date/Time     Date of  Death
Study Trt.    study Trt.    of Death        Death  Flag
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

           Completed
Completed  Efficacy                 Childbearing
Efficacy   Follow-up  Childbearing     Potential
Follow-up  at Week    Potential      for Females
at Week 4  12         for Females            (N)
                                        Subj on      Subj on
                           Concomitant  stable        stable
                                Use of  dose of      dose of
Concomitant Use              SSRI/SNRI  SSRI/SNRI  SSRI/SNRI
of SSRI/SNRI                       (N)  IRT          IRT (N)
Subj on      Subj on
stable        stable
dose of      dose of
SSRI/SNRI  SSRI/SNRI
EDC          EDC (N)      SITE    site_n      trtn  trt
          Analysis                  Planned
          Sequence  Planned       Treatment  Actual
 SITEIDN    Number  Treatment           (N)  Treatment
   Actual  Analysis
Treatment     Visit  Analysis         Visit
      (N)       (N)  Visit           Number  Visit
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

Analysis
  Window
   Visit  Analysis      Parameter
     (N)  Window Visit  Code
                                          Baseline
                                          Record    Analaysis
Parameter                                 Flag           Date
          Analysis  Analysis
Analysis     Date/  Relative  Parameter     Parameter
    Time      Time       Day  Category 1    Category 2
                                            Percentage
                                    Change      Change
Analysis  Analysis      Baseline      from        from
   Value  Value (C)        Value  Baseline    Baseline
 Duration
       of  Time-Dependent  Time-Dependent  Time-Dependent
Treatment       covariate       covariate       covariate
 in Weeks      for Week 1      for Week 4      for Week 8
                              Criterion
                              1
Time-Dependent                Evaluation
 covariate for  Analysis      Result      Analysis
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

       Week 12  Criterion 1   Flag        Criterion 2
Criterion                 Criterion                 Criterion
2                         3                         4
Evaluation                Evaluation                Evaluation
Result      Analysis      Result      Analysis      Result
Flag        Criterion 3   Flag        Criterion 4   Flag
Analysis  Analysis  Analysis
Record    Record    Record
Flag 01   Flag 02   Flag 03
ƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒ
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

JZP150-201            JZP150-201-1973-1001                    
19731001                                          
1973                  USA      1992-06-30          29  YEARS
<=65 years                                                 1
<=45 years                                                 1
F           2
ASIAN                                               19731001/29/
                                                    F/A         
29/F             29/A/F      
Non-Hispanic or Latino                                      2
    68.0     155.0      27.6  2022-03-07  2022-03-07  2022-03-30
2022-06-14  2022-03-30  2022-06-28  Dummy Treatment B
B                     Dummy Treatment B  B                   
JZP150 4 mg           2  JZP150 4 mg           2  30MAR2022
14JUN2022  Y           Y                                 
Y           Y           Y         Y         Y          N        
1992-06-30  Sherry Soefje                  COMPLETED   
28JUN2022                                                    
              COMPLETED                                         
                                                          
N          N          Y                        1
Absence                              2  No                 2
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

No                 2      1973        13         2  JZP150 4 mg 
      13       535  JZP150 4 mg           2  JZP150 4 mg 
        2         0  Baseline             0  Baseline    
       0  Baseline      PTSDTSEV 
PTSD total - Severity                     Y             22733
                          -1  CAPS-5 Past   PTSD totals 
                              Week          - Sum of    
                                            subtotals   
                                            (B+C+D+E)   
      30  30                  30                      
       11               0               0               0
             0                                        
                                                              
Y                   Y       
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

JZP150-201            JZP150-201-1973-1001                    
19731001                                          
1973                  USA      1992-06-30          29  YEARS
<=65 years                                                 1
<=45 years                                                 1
F           2
ASIAN                                               19731001/29/
                                                    F/A         
29/F             29/A/F      
Non-Hispanic or Latino                                      2
    68.0     155.0      27.6  2022-03-07  2022-03-07  2022-03-30
2022-06-14  2022-03-30  2022-06-28  Dummy Treatment B
B                     Dummy Treatment B  B                   
JZP150 4 mg           2  JZP150 4 mg           2  30MAR2022
14JUN2022  Y           Y                                 
Y           Y           Y         Y         Y          N        
1992-06-30  Sherry Soefje                  COMPLETED   
28JUN2022                                                    
              COMPLETED                                         
                                                          
N          N          Y                        1
Absence                              2  No                 2
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

No                 2      1973        13         2  JZP150 4 mg 
      13       537  JZP150 4 mg           2  JZP150 4 mg 
        2        12  Week 12             12  Week 12     
      12  Week 12       PTSDTSEV 
PTSD total - Severity                                   22810
                          77  CAPS-5 Past   PTSD totals 
                              Week          - Sum of    
                                            subtotals   
                                            (B+C+D+E)   
      19  19                  30       -11    -36.6667
       11               0               0               0
             0                            < 30%       
                                          improvement 
                                          on the      
                                          CAPS-5 total
                                          score from  
                                          Baseline to 
                                          Week 12     
Y                                                             
Y                   Y       
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

JZP150-201            JZP150-201-1973-1002                    
19731002                                          
1973                  USA      2000-04-23          21  YEARS
<=65 years                                                 1
<=45 years                                                 1
F           2
WHITE                                               19731002/21/
                                                    F/W         
21/F             21/W/F      
Non-Hispanic or Latino                                      2
    66.5     169.0      23.4  2022-04-18  2022-04-18  2022-05-06
2022-07-26  2022-05-06  2022-08-15  Dummy Treatment C
C                     Dummy Treatment C  C                   
Placebo               3  Placebo               3  06MAY2022
26JUL2022  Y           Y                                 
Y           Y           Y         Y         Y          Y        
2000-04-23  Sherry Soefje                  COMPLETED   
15AUG2022                                                    
              COMPLETED                                         
                                                          
N          N          Y                        1
Presence                             1  Yes                1
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

Yes                1      1973        13         3  Placebo     
      13       535  Placebo               3  Placebo     
        3         0  Baseline             0  Baseline    
       0  Baseline      PTSDTSEV 
PTSD total - Severity                     Y             22770
                          -1  CAPS-5 Past   PTSD totals 
                              Week          - Sum of    
                                            subtotals   
                                            (B+C+D+E)   
      35  35                  35                      
       12               0               0               0
             0                                        
                                                              
Y                   Y       
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

JZP150-201            JZP150-201-1973-1002                    
19731002                                          
1973                  USA      2000-04-23          21  YEARS
<=65 years                                                 1
<=45 years                                                 1
F           2
WHITE                                               19731002/21/
                                                    F/W         
21/F             21/W/F      
Non-Hispanic or Latino                                      2
    66.5     169.0      23.4  2022-04-18  2022-04-18  2022-05-06
2022-07-26  2022-05-06  2022-08-15  Dummy Treatment C
C                     Dummy Treatment C  C                   
Placebo               3  Placebo               3  06MAY2022
26JUL2022  Y           Y                                 
Y           Y           Y         Y         Y          Y        
2000-04-23  Sherry Soefje                  COMPLETED   
15AUG2022                                                    
              COMPLETED                                         
                                                          
N          N          Y                        1
Presence                             1  Yes                1
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

Yes                1      1973        13         3  Placebo     
      13       537  Placebo               3  Placebo     
        3        12  Week 12             12  Week 12     
      12  Week 12       PTSDTSEV 
PTSD total - Severity                                   22852
                          82  CAPS-5 Past   PTSD totals 
                              Week          - Sum of    
                                            subtotals   
                                            (B+C+D+E)   
      20  20                  35       -15    -42.8571
       12               0               0               0
             0                            < 30%       
                                          improvement 
                                          on the      
                                          CAPS-5 total
                                          score from  
                                          Baseline to 
                                          Week 12     
Y                                                             
Y                   Y       
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

JZP150-201            JZP150-201-1973-1004                    
19731004                                          
1973                  USA      1991-01-22          31  YEARS
<=65 years                                                 1
<=45 years                                                 1
M           1
WHITE                                               19731004/31/
                                                    M/W         
31/M             31/W/M      
Non-Hispanic or Latino                                      2
    78.3     174.0      25.9  2022-05-03  2022-05-03  2022-05-18
2022-05-25  2022-05-18  2022-06-08  Dummy Treatment B
B                     Dummy Treatment B  B                   
JZP150 4 mg           2  JZP150 4 mg           2  18MAY2022
25MAY2022  Y           Y                                 
Y           Y           Y         Y         N          N        
1991-01-22  Sherry Soefje                  DISCONTINUED
08JUN2022  ENROLLED IN ERROR                                 
THE PATIENT   DISCONTINUED                                      
WAS ENROLLED                                                    
IN ERROR AND                                                    
REFUSED TO                                                      
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

COMPLETE                                                        
FOLLOW-UP                                                       
VISITS AFTER                                                    
WITHDRAWING                                                     
CONSENT.                                                        
ENROLLED IN   THE PATIENT                                 
ERROR         WAS ENROLLED                                
              IN ERROR AND                                
              REFUSED TO                                  
              COMPLETE                                    
              FOLLOW-UP                                   
              VISITS AFTER                                
              WITHDRAWING                                 
              CONSENT.                                    
N          N                                    
Absence                              2  No                 2
No                 2      1973        13         2  JZP150 4 mg 
      13       179  JZP150 4 mg           2  JZP150 4 mg 
        2         0  Baseline             0  Baseline    
       0  Baseline      PTSDTSEV 
PTSD total - Severity                     Y             22782
                          -1  CAPS-5 Past   PTSD totals 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                              Week          - Sum of    
                                            subtotals   
                                            (B+C+D+E)   
      30  30                  30                      
        1               0               1               2
             2                                        
                                                              
Y                   Y       
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

JZP150-201            JZP150-201-1973-1006                    
19731006                                          
1973                  USA      1994-09-02          27  YEARS
<=65 years                                                 1
<=45 years                                                 1
F           2
WHITE                                               19731006/27/
                                                    F/W         
27/F             27/W/F      
Non-Hispanic or Latino                                      2
    57.4     162.0      22.0  2022-07-14  2022-07-14  2022-08-16
2022-11-06  2022-08-16  2022-11-06  Dummy Treatment C
C                     Dummy Treatment C  C                   
Placebo               3  Placebo               3  16AUG2022
06NOV2022  Y           Y                                 
Y           Y           Y         Y         N          Y        
1994-09-02  Sherry Soefje                  ONGOING     
                                                             
              ONGOING                                           
                                                          
N          N          Y                        1
Absence                              2  No                 2
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

No                 2      1973        13         3  Placebo     
      13       535  Placebo               3  Placebo     
        3         0  Baseline             0  Baseline    
       0  Baseline      PTSDTSEV 
PTSD total - Severity                     Y             22866
                          -7  CAPS-5 Past   PTSD totals 
                              Week          - Sum of    
                                            subtotals   
                                            (B+C+D+E)   
      40  40                  40                      
       12               0               0               0
             0                                        
                                                              
Y                   Y       
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

JZP150-201            JZP150-201-1973-1006                    
19731006                                          
1973                  USA      1994-09-02          27  YEARS
<=65 years                                                 1
<=45 years                                                 1
F           2
WHITE                                               19731006/27/
                                                    F/W         
27/F             27/W/F      
Non-Hispanic or Latino                                      2
    57.4     162.0      22.0  2022-07-14  2022-07-14  2022-08-16
2022-11-06  2022-08-16  2022-11-06  Dummy Treatment C
C                     Dummy Treatment C  C                   
Placebo               3  Placebo               3  16AUG2022
06NOV2022  Y           Y                                 
Y           Y           Y         Y         N          Y        
1994-09-02  Sherry Soefje                  ONGOING     
                                                             
              ONGOING                                           
                                                          
N          N          Y                        1
Absence                              2  No                 2
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

No                 2      1973        13         3  Placebo     
      13       537  Placebo               3  Placebo     
        3        12  Week 12             12  Week 12     
      12  Week 12       PTSDTSEV 
PTSD total - Severity                                   22952
                          80  CAPS-5 Past   PTSD totals 
                              Week          - Sum of    
                                            subtotals   
                                            (B+C+D+E)   
      34  34                  40        -6         -15
       12               0               0               0
             0                            < 30%       
                                          improvement 
                                          on the      
                                          CAPS-5 total
                                          score from  
                                          Baseline to 
                                          Week 12     
Y                                                             
Y                   Y       
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

JZP150-201            JZP150-201-1973-1007                    
19731007                                          
1973                  USA      1975-09-01          46  YEARS
<=65 years                                                 1
>45 years                                                  2
F           2
WHITE                                               19731007/46/
                                                    F/W         
46/F             46/W/F      
Hispanic or Latino                                          1
    81.0     162.0      30.9  2022-08-16  2022-08-16  2022-08-30
2022-11-06  2022-08-30  2022-11-06  Dummy Treatment C
C                     Dummy Treatment C  C                   
Placebo               3  Placebo               3  30AUG2022
06NOV2022  Y           Y                                 
Y           Y           Y         Y         N          Y        
1975-09-01  Sherry Soefje                  ONGOING     
                                                             
              ONGOING                                           
                                                          
N          N          Y                        1
Presence                             1  Yes                1
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

Yes                1      1973        13         3  Placebo     
      13       357  Placebo               3  Placebo     
        3         0  Baseline             0  Baseline    
       0  Baseline      PTSDTSEV 
PTSD total - Severity                                   22887
                           1  CAPS-5 Past   PTSD totals 
                              Week          - Sum of    
                                            subtotals   
                                            (B+C+D+E)   
      33  33                                          
       10               0               0               0
             1                                        
                                                              
Y                   Y       
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

Study Identifier      Unique Subject Identifier
Subject Identifier for the Study
Study Site                     Date/Time               Age
Identifier            Country  of Birth           Age  Units
                                                      Pooled
                                                         Age
                                                       Group
Pooled Age Group 1                                     1 (N)
                                                      Pooled
                                                         Age
                                                       Group
Pooled Age Group 2                                     2 (N)
Sex   Sex (N)
                                                    Subject
                                                    Identifier
                                                    for Study
Race                                                for Listing
Age/Sex          Age/Race/Sex
                                                    Ethnicity
Ethnicity                                                 (N)
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                    Baseline
                        Body  Date/Time               Date/Time
Baseline  Baseline      Mass  of             Date of  of First
  Weight    Height     Index  Informed      Informed  Study
    (kg)      (cm)  (kg/m^2)  Consent        Consent  Treatment
Date/Time   Subject     Subject
of Last     Reference   Reference
Study       Start       Stop        Description of
Treatment   Date/Time   Date/Time   Actual Arm
Description of        Description of     Description of
Actual Arm Code       Planned Arm        Planned Arm Code
                Planned                   Actual    Date of
Planned       Treatment  Actual        Treatment      First
Treatment           for  Treatment           for   Exposure
for Period       Period  for Period       Period         to
01               01 (N)  01               01 (N)  Treatment
  Date of
     Last
 Exposure  Safety      Enrolled    PK          PD
       to  Population  Population  Population  Population
Treatment  Flag        Flag        Flag        Flag
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                                  Modified  Completed  PTSD
RAND        Screened    Full      Full      Safety     Diagnosis
Population  Population  Analysis  Analysis  Follow-up  History
Flag        Flag        set Flag  Set       Flg        Flag
                                           Discon.
   Date of                                 Early from
 Birth (N)  Investigator Name              Study
  Discon.
    Early
     from
    Study
     Date  Reas. for Disc. Early from Study
Reas. for
Disc. Early
from Study,
Spcy.         Discon.  Early from study Trt.
              Reas. for
Reas. for     Early                                Subject
Disc. of      Discon. from  Date/Time     Date of  Death
Study Trt.    study Trt.    of Death        Death  Flag
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

           Completed
Completed  Efficacy                 Childbearing
Efficacy   Follow-up  Childbearing     Potential
Follow-up  at Week    Potential      for Females
at Week 4  12         for Females            (N)
                                        Subj on      Subj on
                           Concomitant  stable        stable
                                Use of  dose of      dose of
Concomitant Use              SSRI/SNRI  SSRI/SNRI  SSRI/SNRI
of SSRI/SNRI                       (N)  IRT          IRT (N)
Subj on      Subj on
stable        stable
dose of      dose of
SSRI/SNRI  SSRI/SNRI
EDC          EDC (N)      SITE    site_n      trtn  trt
          Analysis                  Planned
          Sequence  Planned       Treatment  Actual
 SITEIDN    Number  Treatment           (N)  Treatment
   Actual  Analysis
Treatment     Visit  Analysis         Visit
      (N)       (N)  Visit           Number  Visit
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

Analysis
  Window
   Visit  Analysis      Parameter
     (N)  Window Visit  Code
                                          Baseline
                                          Record    Analaysis
Parameter                                 Flag           Date
          Analysis  Analysis
Analysis     Date/  Relative  Parameter     Parameter
    Time      Time       Day  Category 1    Category 2
                                            Percentage
                                    Change      Change
Analysis  Analysis      Baseline      from        from
   Value  Value (C)        Value  Baseline    Baseline
 Duration
       of  Time-Dependent  Time-Dependent  Time-Dependent
Treatment       covariate       covariate       covariate
 in Weeks      for Week 1      for Week 4      for Week 8
                              Criterion
                              1
Time-Dependent                Evaluation
 covariate for  Analysis      Result      Analysis
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

       Week 12  Criterion 1   Flag        Criterion 2
Criterion                 Criterion                 Criterion
2                         3                         4
Evaluation                Evaluation                Evaluation
Result      Analysis      Result      Analysis      Result
Flag        Criterion 3   Flag        Criterion 4   Flag
Analysis  Analysis  Analysis
Record    Record    Record
Flag 01   Flag 02   Flag 03
ƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒ
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

JZP150-201            JZP150-201-1983-1001                    
19831001                                          
1983                  USA      1999-03-17          23  YEARS
<=65 years                                                 1
<=45 years                                                 1
F           2
WHITE                                               19831001/23/
                                                    F/W         
23/F             23/W/F      
Hispanic or Latino                                          1
    76.2     152.4      32.8  2022-04-08  2022-04-08  2022-05-07
2022-07-29  2022-05-07  2022-08-12  Dummy Treatment C
C                     Dummy Treatment C  C                   
Placebo               3  Placebo               3  07MAY2022
29JUL2022  Y           Y                                 
Y           Y           Y         Y         Y          N        
1999-03-17  Jesse Carr                     COMPLETED   
12AUG2022                                                    
              COMPLETED                                         
                                                          
N          N          Y                        1
Absence                              2  No                 2
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

No                 2      1983        14         3  Placebo     
      14       535  Placebo               3  Placebo     
        3         0  Baseline             0  Baseline    
       0  Baseline      PTSDTSEV 
PTSD total - Severity                     Y             22764
                          -8  CAPS-5 Past   PTSD totals 
                              Week          - Sum of    
                                            subtotals   
                                            (B+C+D+E)   
      44  44                  44                      
       12               0               0               0
             0                                        
                                                              
Y                   Y       
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

JZP150-201            JZP150-201-1983-1001                    
19831001                                          
1983                  USA      1999-03-17          23  YEARS
<=65 years                                                 1
<=45 years                                                 1
F           2
WHITE                                               19831001/23/
                                                    F/W         
23/F             23/W/F      
Hispanic or Latino                                          1
    76.2     152.4      32.8  2022-04-08  2022-04-08  2022-05-07
2022-07-29  2022-05-07  2022-08-12  Dummy Treatment C
C                     Dummy Treatment C  C                   
Placebo               3  Placebo               3  07MAY2022
29JUL2022  Y           Y                                 
Y           Y           Y         Y         Y          N        
1999-03-17  Jesse Carr                     COMPLETED   
12AUG2022                                                    
              COMPLETED                                         
                                                          
N          N          Y                        1
Absence                              2  No                 2
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

No                 2      1983        14         3  Placebo     
      14       537  Placebo               3  Placebo     
        3        12  Week 12             12  Week 12     
      12  Week 12       PTSDTSEV 
PTSD total - Severity                                   22855
                          84  CAPS-5 Past   PTSD totals 
                              Week          - Sum of    
                                            subtotals   
                                            (B+C+D+E)   
      28  28                  44       -16    -36.3636
       12               0               0               0
             0                            < 30%       
                                          improvement 
                                          on the      
                                          CAPS-5 total
                                          score from  
                                          Baseline to 
                                          Week 12     
Y                                                             
Y                   Y       
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

JZP150-201            JZP150-201-1983-1005                    
19831005                                          
1983                  USA      1981-06-04          40  YEARS
<=65 years                                                 1
<=45 years                                                 1
M           1
WHITE                                               19831005/40/
                                                    M/W         
40/M             40/W/M      
Non-Hispanic or Latino                                      2
    77.5     182.8      23.2  2022-05-06  2022-05-06  2022-05-17
2022-08-08  2022-05-17  2022-08-22  Dummy Treatment B
B                     Dummy Treatment B  B                   
JZP150 4 mg           2  JZP150 4 mg           2  17MAY2022
08AUG2022  Y           Y                                 
Y           Y           Y         Y         Y          Y        
1981-06-04  Jesse Carr                     COMPLETED   
22AUG2022                                                    
              COMPLETED                                         
                                                          
N          N                                    
Absence                              2  No                 2
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

No                 2      1983        14         2  JZP150 4 mg 
      14       535  JZP150 4 mg           2  JZP150 4 mg 
        2         0  Baseline             0  Baseline    
       0  Baseline      PTSDTSEV 
PTSD total - Severity                     Y             22781
                          -1  CAPS-5 Past   PTSD totals 
                              Week          - Sum of    
                                            subtotals   
                                            (B+C+D+E)   
      32  32                  32                      
       12               0               0               0
             0                                        
                                                              
Y                   Y       
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

JZP150-201            JZP150-201-1983-1005                    
19831005                                          
1983                  USA      1981-06-04          40  YEARS
<=65 years                                                 1
<=45 years                                                 1
M           1
WHITE                                               19831005/40/
                                                    M/W         
40/M             40/W/M      
Non-Hispanic or Latino                                      2
    77.5     182.8      23.2  2022-05-06  2022-05-06  2022-05-17
2022-08-08  2022-05-17  2022-08-22  Dummy Treatment B
B                     Dummy Treatment B  B                   
JZP150 4 mg           2  JZP150 4 mg           2  17MAY2022
08AUG2022  Y           Y                                 
Y           Y           Y         Y         Y          Y        
1981-06-04  Jesse Carr                     COMPLETED   
22AUG2022                                                    
              COMPLETED                                         
                                                          
N          N                                    
Absence                              2  No                 2
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

No                 2      1983        14         2  JZP150 4 mg 
      14       537  JZP150 4 mg           2  JZP150 4 mg 
        2        12  Week 12             12  Week 12     
      12  Week 12       PTSDTSEV 
PTSD total - Severity                                   22865
                          84  CAPS-5 Past   PTSD totals 
                              Week          - Sum of    
                                            subtotals   
                                            (B+C+D+E)   
      17  17                  32       -15     -46.875
       12               0               0               0
             0                            < 30%       
                                          improvement 
                                          on the      
                                          CAPS-5 total
                                          score from  
                                          Baseline to 
                                          Week 12     
Y                                                             
Y                   Y       
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

JZP150-201            JZP150-201-1983-1008                    
19831008                                          
1983                  USA      1984-12-01          37  YEARS
<=65 years                                                 1
<=45 years                                                 1
M           1
WHITE                                               19831008/37/
                                                    M/W         
37/M             37/W/M      
Hispanic or Latino                                          1
    82.5     180.3      25.3  2022-05-25  2022-05-25  2022-06-15
2022-09-06  2022-06-15  2022-09-22  Dummy Treatment B
B                     Dummy Treatment B  B                   
JZP150 4 mg           2  JZP150 4 mg           2  15JUN2022
06SEP2022  Y           Y                                 
Y           Y           Y         Y         N          N        
1984-12-01  Jesse Carr                     DISCONTINUED
22SEP2022  LOST TO FU                                        
LOST TO FU    COMPLETED                                         
                                                          
N          N                                    
Absence                              2  No                 2
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

No                 2      1983        14         2  JZP150 4 mg 
      14       714  JZP150 4 mg           2  JZP150 4 mg 
        2         0  Baseline             0  Baseline    
       0  Baseline      PTSDTSEV 
PTSD total - Severity                     Y             22810
                          -1  CAPS-5 Past   PTSD totals 
                              Week          - Sum of    
                                            subtotals   
                                            (B+C+D+E)   
      33  33                  33                      
       12               0               0               0
             0                                        
                                                              
Y                   Y       
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

JZP150-201            JZP150-201-1983-1008                    
19831008                                          
1983                  USA      1984-12-01          37  YEARS
<=65 years                                                 1
<=45 years                                                 1
M           1
WHITE                                               19831008/37/
                                                    M/W         
37/M             37/W/M      
Hispanic or Latino                                          1
    82.5     180.3      25.3  2022-05-25  2022-05-25  2022-06-15
2022-09-06  2022-06-15  2022-09-22  Dummy Treatment B
B                     Dummy Treatment B  B                   
JZP150 4 mg           2  JZP150 4 mg           2  15JUN2022
06SEP2022  Y           Y                                 
Y           Y           Y         Y         N          N        
1984-12-01  Jesse Carr                     DISCONTINUED
22SEP2022  LOST TO FU                                        
LOST TO FU    COMPLETED                                         
                                                          
N          N                                    
Absence                              2  No                 2
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

No                 2      1983        14         2  JZP150 4 mg 
      14       716  JZP150 4 mg           2  JZP150 4 mg 
        2        12  Week 12             12  Week 12     
      12  Week 12       PTSDTSEV 
PTSD total - Severity                                   22894
                          84  CAPS-5 Past   PTSD totals 
                              Week          - Sum of    
                                            subtotals   
                                            (B+C+D+E)   
       0  0                   33       -33        -100
       12               0               0               0
             0                            < 30%       
                                          improvement 
                                          on the      
                                          CAPS-5 total
                                          score from  
                                          Baseline to 
                                          Week 12     
Y                                                             
Y                   Y       
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

Study Identifier      Unique Subject Identifier
Subject Identifier for the Study
Study Site                     Date/Time               Age
Identifier            Country  of Birth           Age  Units
                                                      Pooled
                                                         Age
                                                       Group
Pooled Age Group 1                                     1 (N)
                                                      Pooled
                                                         Age
                                                       Group
Pooled Age Group 2                                     2 (N)
Sex   Sex (N)
                                                    Subject
                                                    Identifier
                                                    for Study
Race                                                for Listing
Age/Sex          Age/Race/Sex
                                                    Ethnicity
Ethnicity                                                 (N)
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                    Baseline
                        Body  Date/Time               Date/Time
Baseline  Baseline      Mass  of             Date of  of First
  Weight    Height     Index  Informed      Informed  Study
    (kg)      (cm)  (kg/m^2)  Consent        Consent  Treatment
Date/Time   Subject     Subject
of Last     Reference   Reference
Study       Start       Stop        Description of
Treatment   Date/Time   Date/Time   Actual Arm
Description of        Description of     Description of
Actual Arm Code       Planned Arm        Planned Arm Code
                Planned                   Actual    Date of
Planned       Treatment  Actual        Treatment      First
Treatment           for  Treatment           for   Exposure
for Period       Period  for Period       Period         to
01               01 (N)  01               01 (N)  Treatment
  Date of
     Last
 Exposure  Safety      Enrolled    PK          PD
       to  Population  Population  Population  Population
Treatment  Flag        Flag        Flag        Flag
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                                  Modified  Completed  PTSD
RAND        Screened    Full      Full      Safety     Diagnosis
Population  Population  Analysis  Analysis  Follow-up  History
Flag        Flag        set Flag  Set       Flg        Flag
                                           Discon.
   Date of                                 Early from
 Birth (N)  Investigator Name              Study
  Discon.
    Early
     from
    Study
     Date  Reas. for Disc. Early from Study
Reas. for
Disc. Early
from Study,
Spcy.         Discon.  Early from study Trt.
              Reas. for
Reas. for     Early                                Subject
Disc. of      Discon. from  Date/Time     Date of  Death
Study Trt.    study Trt.    of Death        Death  Flag
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

           Completed
Completed  Efficacy                 Childbearing
Efficacy   Follow-up  Childbearing     Potential
Follow-up  at Week    Potential      for Females
at Week 4  12         for Females            (N)
                                        Subj on      Subj on
                           Concomitant  stable        stable
                                Use of  dose of      dose of
Concomitant Use              SSRI/SNRI  SSRI/SNRI  SSRI/SNRI
of SSRI/SNRI                       (N)  IRT          IRT (N)
Subj on      Subj on
stable        stable
dose of      dose of
SSRI/SNRI  SSRI/SNRI
EDC          EDC (N)      SITE    site_n      trtn  trt
          Analysis                  Planned
          Sequence  Planned       Treatment  Actual
 SITEIDN    Number  Treatment           (N)  Treatment
   Actual  Analysis
Treatment     Visit  Analysis         Visit
      (N)       (N)  Visit           Number  Visit
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

Analysis
  Window
   Visit  Analysis      Parameter
     (N)  Window Visit  Code
                                          Baseline
                                          Record    Analaysis
Parameter                                 Flag           Date
          Analysis  Analysis
Analysis     Date/  Relative  Parameter     Parameter
    Time      Time       Day  Category 1    Category 2
                                            Percentage
                                    Change      Change
Analysis  Analysis      Baseline      from        from
   Value  Value (C)        Value  Baseline    Baseline
 Duration
       of  Time-Dependent  Time-Dependent  Time-Dependent
Treatment       covariate       covariate       covariate
 in Weeks      for Week 1      for Week 4      for Week 8
                              Criterion
                              1
Time-Dependent                Evaluation
 covariate for  Analysis      Result      Analysis
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

       Week 12  Criterion 1   Flag        Criterion 2
Criterion                 Criterion                 Criterion
2                         3                         4
Evaluation                Evaluation                Evaluation
Result      Analysis      Result      Analysis      Result
Flag        Criterion 3   Flag        Criterion 4   Flag
Analysis  Analysis  Analysis
Record    Record    Record
Flag 01   Flag 02   Flag 03
ƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒ
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

JZP150-201            JZP150-201-1986-1006                    
19861006                                          
1986                  USA      1982-10-25          39  YEARS
<=65 years                                                 1
<=45 years                                                 1
F           2
BLACK OR AFRICAN AMERICAN                           19861006/39/
                                                    F/B         
39/F             39/B/F      
Non-Hispanic or Latino                                      2
    97.5     167.6      34.7  2022-09-22  2022-09-22  2022-10-12
2022-11-06  2022-10-12  2022-11-06  Dummy Treatment C
C                     Dummy Treatment C  C                   
Placebo               3  Placebo               3  12OCT2022
06NOV2022  Y           Y                                 
Y           Y           Y         Y         N          N        
1982-10-25  Diane Highum                   ONGOING     
                                                             
              ONGOING                                           
                                                          
N          N          Y                        1
Absence                              2  No                 2
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

No                 2      1986        15         3  Placebo     
      15       179  Placebo               3  Placebo     
        3         0  Baseline             0  Baseline    
       0  Baseline      PTSDTSEV 
PTSD total - Severity                                   22930
                           1  CAPS-5 Past   PTSD totals 
                              Week          - Sum of    
                                            subtotals   
                                            (B+C+D+E)   
      47  47                                          
        4               0               0               1
             2                                        
                                                              
Y                   Y       
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

Study Identifier      Unique Subject Identifier
Subject Identifier for the Study
Study Site                     Date/Time               Age
Identifier            Country  of Birth           Age  Units
                                                      Pooled
                                                         Age
                                                       Group
Pooled Age Group 1                                     1 (N)
                                                      Pooled
                                                         Age
                                                       Group
Pooled Age Group 2                                     2 (N)
Sex   Sex (N)
                                                    Subject
                                                    Identifier
                                                    for Study
Race                                                for Listing
Age/Sex          Age/Race/Sex
                                                    Ethnicity
Ethnicity                                                 (N)
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                    Baseline
                        Body  Date/Time               Date/Time
Baseline  Baseline      Mass  of             Date of  of First
  Weight    Height     Index  Informed      Informed  Study
    (kg)      (cm)  (kg/m^2)  Consent        Consent  Treatment
Date/Time   Subject     Subject
of Last     Reference   Reference
Study       Start       Stop        Description of
Treatment   Date/Time   Date/Time   Actual Arm
Description of        Description of     Description of
Actual Arm Code       Planned Arm        Planned Arm Code
                Planned                   Actual    Date of
Planned       Treatment  Actual        Treatment      First
Treatment           for  Treatment           for   Exposure
for Period       Period  for Period       Period         to
01               01 (N)  01               01 (N)  Treatment
  Date of
     Last
 Exposure  Safety      Enrolled    PK          PD
       to  Population  Population  Population  Population
Treatment  Flag        Flag        Flag        Flag
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                                  Modified  Completed  PTSD
RAND        Screened    Full      Full      Safety     Diagnosis
Population  Population  Analysis  Analysis  Follow-up  History
Flag        Flag        set Flag  Set       Flg        Flag
                                           Discon.
   Date of                                 Early from
 Birth (N)  Investigator Name              Study
  Discon.
    Early
     from
    Study
     Date  Reas. for Disc. Early from Study
Reas. for
Disc. Early
from Study,
Spcy.         Discon.  Early from study Trt.
              Reas. for
Reas. for     Early                                Subject
Disc. of      Discon. from  Date/Time     Date of  Death
Study Trt.    study Trt.    of Death        Death  Flag
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

           Completed
Completed  Efficacy                 Childbearing
Efficacy   Follow-up  Childbearing     Potential
Follow-up  at Week    Potential      for Females
at Week 4  12         for Females            (N)
                                        Subj on      Subj on
                           Concomitant  stable        stable
                                Use of  dose of      dose of
Concomitant Use              SSRI/SNRI  SSRI/SNRI  SSRI/SNRI
of SSRI/SNRI                       (N)  IRT          IRT (N)
Subj on      Subj on
stable        stable
dose of      dose of
SSRI/SNRI  SSRI/SNRI
EDC          EDC (N)      SITE    site_n      trtn  trt
          Analysis                  Planned
          Sequence  Planned       Treatment  Actual
 SITEIDN    Number  Treatment           (N)  Treatment
   Actual  Analysis
Treatment     Visit  Analysis         Visit
      (N)       (N)  Visit           Number  Visit
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

Analysis
  Window
   Visit  Analysis      Parameter
     (N)  Window Visit  Code
                                          Baseline
                                          Record    Analaysis
Parameter                                 Flag           Date
          Analysis  Analysis
Analysis     Date/  Relative  Parameter     Parameter
    Time      Time       Day  Category 1    Category 2
                                            Percentage
                                    Change      Change
Analysis  Analysis      Baseline      from        from
   Value  Value (C)        Value  Baseline    Baseline
 Duration
       of  Time-Dependent  Time-Dependent  Time-Dependent
Treatment       covariate       covariate       covariate
 in Weeks      for Week 1      for Week 4      for Week 8
                              Criterion
                              1
Time-Dependent                Evaluation
 covariate for  Analysis      Result      Analysis
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

       Week 12  Criterion 1   Flag        Criterion 2
Criterion                 Criterion                 Criterion
2                         3                         4
Evaluation                Evaluation                Evaluation
Result      Analysis      Result      Analysis      Result
Flag        Criterion 3   Flag        Criterion 4   Flag
Analysis  Analysis  Analysis
Record    Record    Record
Flag 01   Flag 02   Flag 03
ƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒ
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

JZP150-201            JZP150-201-1990-1003                    
19901003                                          
1990                  USA      1970-12-11          51  YEARS
<=65 years                                                 1
>45 years                                                  2
F           2
WHITE                                               19901003/51/
                                                    F/W         
51/F             51/W/F      
Non-Hispanic or Latino                                      2
    89.5     160.0      34.6  2022-09-22  2022-09-22  2022-10-14
2022-11-06  2022-10-14  2022-11-06  Dummy Treatment C
C                     Dummy Treatment C  C                   
Placebo               3  Placebo               3  14OCT2022
06NOV2022  Y           Y                                 
Y           Y           Y         Y         N          N        
1970-12-11  Jeffrey Ries                   ONGOING     
                                                             
              ONGOING                                           
                                                          
N          N          Y                        1
Absence                              2  No                 2
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

No                 2      1990        16         3  Placebo     
      16       179  Placebo               3  Placebo     
        3         0  Baseline             0  Baseline    
       0  Baseline      PTSDTSEV 
PTSD total - Severity                     Y             22931
                          -1  CAPS-5 Past   PTSD totals 
                              Week          - Sum of    
                                            subtotals   
                                            (B+C+D+E)   
      37  37                  37                      
        3               0               1               2
             2                                        
                                                              
Y                   Y       
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
